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Apathy is highly prevalent in dementia and is also seen in mild cognitive impairment and the general 3 
population. Apathy contributes to failure to undertake daily activities, and can lead to health 4 
problems or crises.  It is therefore important to assess apathy. However, there is currently no gold-5 
standard measure of apathy. A comprehensive systematic review of the measurement properties of 6 
apathy scales is required. 7 
Methods 8 
A systematic review was registered with PROSPERO (ID: CRD42018094390). MEDLINE, EMBASE, 9 
PsycINFO and CINAHL were searched for studies that aimed to develop or assess the validity or 10 
reliability of an apathy scale in participants over 65 years, living in the community. A systematic 11 
review was conducted in line with the COnsensus-based Standards for the selection of health 12 
Measurement INstruments (COSMIN) procedure for reviewing patient-reported outcome measures. 13 
The studies’ risk of bias were assessed and all relevant measurement properties were assessed for 14 
quality. Results were pooled and rated using a modified Grading of Recommendations Assessment, 15 
Development and Evaluation procedure. 16 
Results 17 
Fifty-seven publications regarding 18 measures and 39 variations met the eligibility criteria. The 18 
methodological quality of individual studies ranged from inadequate to very good and measurement 19 
properties ranged from insufficient to sufficient. Similarly, the overall evidence for measurement 20 
properties ranged from very low to high quality. The Apathy Evaluation Scale and Lille Apathy Rating 21 
Scale had sufficient content validity, reliability, construct validity, and where applicable, structural 22 
validity and internal consistency. 23 
Conclusion 24 
Numerous scales are available to assess apathy, with varying psychometric properties. The Apathy 25 
Evaluation Scale and Lille Apathy Rating Scale are recommended for measuring apathy in older adults 26 
and people living with dementia. The apathy dimension of the commonly-used Neuropsychiatric 27 




Apathy is a multidimensional construct, defined as quantitatively reduced behavioural, cognitive, 30 
emotional or social (goal-directed) activity which may include reduced motivation, initiative, effort, 31 
interest, concern about self or others, and affect [1]. Apathy is the most common neuropsychiatric 32 
symptom of dementia [2] and is reported in 15% to 92% of people with dementia [3], and 12% to 33 
40% of people with Mild Cognitive Impairment (MCI) [4,5]. Apathy is associated with important 34 
outcomes in dementia and MCI, including disabilities in everyday functioning [6], increased carer 35 
burden [7–10], worse adherence to interventions [11,12], and worse quality of life [13]. Prevention 36 
or management of apathy in dementia has been identified as a priority area for research [14]. Apathy 37 
in older adults is associated with increased likelihood of subsequent cognitive impairment [15], 38 
conversion from MCI to dementia [5,16], and worse disease progression [17,18]. It is therefore 39 
important to research across the spectrum of cognitive impairment [19], including older adults who 40 
otherwise appear cognitively unimpaired.  41 
There is no gold-standard measure of apathy [20]. Two systematic reviews of apathy scales have 42 
been published; the first examined scales developed for people with neurodegenerative conditions 43 
such as Parkinson’s Disease, Amyotrophic Lateral Sclerosis, and dementia [21], whilst the second 44 
examined evidence for measurement properties in people with dementia [22]. The first systematic 45 
review only included studies that assessed both validity and reliability of a scale within a single 46 
publication. Whilst a scale should be both valid and reliable, separately published studies of reliability 47 
and validity can collectively offer sufficient evidence for both. The latter review used limited search 48 
criteria and it is unclear when the search was conducted. Therefore, important studies regarding the 49 
quality of apathy scales may have been missed.  50 
Both of these systematic reviews used the Quality Assessment of Diagnostic Accuracy Studies 51 
(QUADAS) tool, designed for studies of diagnostic accuracy [23], not other measurement properties, 52 
such as reliability. It is not clear how these reviews rated properties such as reliability using the 53 
QUADAS criteria that refer to a ‘reference standard’, which is only relevant to properties such as 54 
criterion validity. The COnsensus-based Standards for the selection of health Measurement 55 
INstruments (COSMIN) programme of work has since published guidance for conducting and 56 
reporting systematic reviews of health measures, with methodological quality standards and 57 
measurement property quality criteria that enables a systematic and standardized critical 58 
examination of all key measurement properties of scales [24,25]. 59 
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The aim of this study was to assess and compare the quality of measurement properties (i.e. the 60 
reliability and validity) and characteristics, of apathy scales and to analyse the quality of the evidence 61 
in healthy older adults and people with dementia, in accordance with COSMIN guidance. 62 
Methods 63 
Design 64 
This systematic review protocol was registered with PROSPERO (ID: CRD42018094390) and published 65 
prior to analysis [26]. The COSMIN methodology for conducting systematic reviews of patient 66 
reported outcome measures [24,25,27] was followed. Properties were assessed in relation to both 67 
people with dementia and older adults. Some additional decisions were required for this review, 68 
which were based on literature, discussions with the review team, and PPI input. For example, there 69 
is no gold standard time interval for test-retest reliability studies [28] though a time interval of two 70 
weeks is common [29]. Apathy is a relatively stable, but not an enduring trait, so a time interval that 71 
exceeded 28 days or 1 month was considered inappropriate. A time interval of less than 3 days for 72 
people with memory problems, and less than 7 days for people without memory problems, was also 73 
considered inappropriate as memory of previous answers may inflate reliability estimates. These 74 
were arbitrary numbers chosen in lieu of guidance, but was deemed acceptable by the review team 75 
and PPI members. 76 
Searching, screening and selection 77 
MEDLINE (In-Process, Other Non-Indexed Citations and 1946 onwards) EMBASE (1980 onwards), 78 
PsycINFO (1806 onwards, via Ovid) and CINAHL (1937 onwards) were searched using the specified 79 
search strategy on 18th April 2018, and the search was re-ran in the same databases on 6th May 2020. 80 
The reference lists of the included studies, and of any relevant review articles, were also examined 81 
for relevant publications. The COSMIN search strategy for identifying research on the development, 82 
validity or reliability of health related outcome measures [30] formed part of the search strategy, 83 
along with apathy related terms (e.g. apathy; lack of or diminished motivation, interest, initiative; 84 
emotional blunting; emotional responsiveness; abulia; anhedonia; frontal symptom; asocial; avoliton; 85 
lassitude). The search strategy was first created for MEDLINE (Supplementary Additional File 1), then 86 
the subject headings and syntax were adapted for the other databases.  87 
Inclusion criteria: studies that aimed to develop or assess the measurement properties of an apathy 88 
scale based on patient or informant reports or interviewer or clinician ratings; primary research; full-89 
5 
 
text publication; majority of participants living in the community; majority of participants aged 65 or 90 
over. Exclusion criteria: studies assessing scales of apathy in a specific context such as work 91 
performance, or following an event, such as in post-traumatic stress disorder and post-natal 92 
depression. Additionally, development studies were included regardless of eligibility criteria if they 93 
pertained to an apathy scale that was included in one of the eligible studies. 94 
The titles and abstracts of articles were screened (by ClB) to assess whether they met the eligibility 95 
criteria. All included full-text articles were assessed against eligibility criteria (by ClB), and a randomly 96 
selected 10% of articles was independently assessed by a second reviewer (CaB). Articles for which 97 
there was disagreement between reviewers were discussed and an agreement was reached. 98 
Data extraction and assessment 99 
Data extraction was conducted (by ClB) into a data extraction table (Supplementary Additional File 100 
2). Data extraction of 20% of publications was checked by second reviewers (CaB; VvdW) and no 101 
errors were found. For each study included in the review, data relating to study characteristics and 102 
methods, participant characteristics, and measurement characteristics and properties were 103 
extracted. Measurement properties included that of reliability (internal consistency, measurement 104 
error and test-retest and interrater reliability) and validity (content validity, structural validity, 105 
hypothesis testing for construct validity), as defined by the COSMIN taxonomy [31]. Criterion validity 106 
and responsiveness were not reviewed, as there is no gold standard measure of apathy against which 107 
to assess the scales. 108 
Risk of bias in individual studies was examined using the COSMIN risk of bias checklist [25,27] 109 
(Supplementary Additional File 3). The results of studies were assessed using COSMIN criteria for 110 
good measurement properties [24,25]. Publications were assigned a number and randomly selected 111 
for second reviewer ratings using a random number function in Microsoft Excel. Twenty-one percent 112 
(N=12) of publications were independently rated by second reviewers for risk of bias and against 113 
criteria for good measurement properties (SG and VvdW). Where there was disagreement, this was 114 
discussed between the two raters (ClB and SG; ClB and VvdW) and any remaining disagreements 115 
were discussed with a third rater. 116 
Synthesis of results 117 
Studies meeting the eligibility criteria were summarised using a narrative synthesis. For each scale, 118 
the measurement properties reported in the corresponding studies were summarised, and the 119 
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quality of these synthesized results was assessed using the criteria for good measurement properties 120 
[24,32]. Where there were different versions of scale, results were pooled providing they were not 121 
contradictory. The COSMIN modified GRADE approach [24,25] was used to assess the quality of the 122 
cumulative evidence for each measurement property for each scale. COSMIN procedure for the 123 
recommendations of scales in systematic reviews [24] was used to guide the recommendations 124 
made.  125 
Results 126 
Study selection 127 
The initial search resulted in 9645 records and the re-executed search identified an additional 2339 128 
records (Figure 1). Following removal of duplicates, there were 7811 records. A further 24 records 129 
were identified through screening reference lists and manual searching. After screening of titles and 130 
abstracts, 185 remained for full-text screening. Following full-text screening, fifty-seven publications 131 
of 18 distinct scales (and 39 variations) were identified as meeting eligibility criteria (Supplementary 132 
Table S1 in Additional File 4). Many publications reported multiple studies, even for the same 133 
measurement property, for example, where the measurement property was assessed and reported 134 
for different populations or different versions of the same scale, or where different methods were 135 
used to assess the same measurement property. 136 
The measurement properties and study characteristics are reported in Supplementary Table S2 in 137 
Additional File 4. Seven apathy-specific scales were identified: The Apathy Evaluation Scale (AES) 138 
[33]; Apathy Inventory (AI) [34]; Apathy Motivation Index (AMI) [35]; Starkstein Apathy Scale (AS) 139 
[36]; Dementia Apathy Interview and Rating (DAIR) [37]; Dimensional Apathy Scale (DAS) [38]; The 140 
Lille Apathy Rating Scale (LARS) [39]. Apathy subscales were present in eleven global scales designed 141 
to assess a variety of constructs (such as dementia severity, and neuropsychiatric symptoms): 142 
Alzheimer’s Disease and Related Dementias mood scale (ADRD) [40,41]; Behavioural and Mood 143 
Disturbance Scale (BMDS) [42]; Behavioral Syndromes Scale for Dementia (BSSD) [43]; Dysexecutive 144 
Questionnaire (DEX) [44]; Frontal Systems Behavior Scale (FrSBe) [45]; Geriatric Depression Scale 145 
(GDS) [46,47]; Behavioural Rating Scale for Geriatric Inpatients (GIP) [48]; Index of Mental Decline 146 
(IMD) [49]; Key Behaviours Change Inventory (KBCI) [50]; Neuropsychiatric Inventory (NPI) [51]; 147 
Unified Parkinson’s Disease Rating Scale (UPDRS) [52]. Only the measurement properties of apathy 148 
subscales were assessed, not the overall global scale. Of the publications that met the inclusion 149 
criteria, there was one each that pertained to the AD-RD, BMDS, BSSD, DEX, GIP, IMD, KBCI, AMI, 150 
7 
 
DAIR, two regarding the FrSBe and GDS, three regarding the AI and LARS, four regarding the UPDRS, 151 
five regarding the DAS, eight regarding the AS, nine regarding the AES, and twelve regarding the NPI. 152 
The majority of scales required respondents to select responses from a Likert scale, in relation to 153 
various questions or items. Number of scored items in the scales ranged from one to 33. Recall 154 
periods ranged from one week to one month, with some scales not specifying a recall period, or 155 
specifying since the onset of a disease.  156 
Risk of Bias 157 
Results of the individual studies and their risk of bias ratings are reported in the online 158 
supplementary material (Supplementary Tables S3 – S5 in Additional File 4). No studies assessed 159 
cross-cultural validity, so this is not discussed nor included in the tables. Literature pertaining to 160 
development was obtained for all scales except the DEX, GIP, and FrSBe. Few additional content 161 
validity studies were available that met the eligibility criteria. Most content validity and development 162 
studies had indeterminate results, due to a poorly reported or inadequate method. Twenty-seven 163 
studies of structural validity across 16 publications met the inclusion criteria [33,37,53–66]. Three 164 
studies had very good methodological quality, as most studies used exploratory factor analysis or 165 
principle component analysis to assess structural validity, instead of the preferred confirmatory 166 
factory analysis or item response theory methods. Internal consistency was assessed by 31 167 
publications [33,34,36,37,43,53,55–79] and was considered a valid assessment (i.e. the scale was 168 
based on a reflective model) in 38 studies. Some results were indeterminate due to lack of evidence 169 
that the scale was unidimensional, and therefore uncertainty regarding whether internal consistency 170 
should apply. There were 38 inter-rater or test-retest reliability studies 171 
[33,34,36,37,40,42,43,53,65,70,73,76,77,79–88] from 23 publications. None were of very good 172 
methodological quality, and just one was of adequate quality. Methodological quality of reliability 173 
studies was mostly limited as a result of not using the optimal statistical method, such as the use of 174 
Kappa rather than weighted Kappa, or Pearson or Spearman correlation instead of Intraclass 175 
Correlation Coefficient (ICC). Where the most appropriate method was used, the model or formula of 176 
ICC or weighted Kappa was often not reported. Six studies of measurement error were conducted 177 
across four publications [37,56,77,82]. For all but one study, it was not possible to draw conclusions, 178 
due to lack of appropriate anchor-based estimates of Minimal Important Change (MIC) for any of the 179 
scales. One hundred and eighty studies of hypothesis testing for construct (including convergent, 180 
divergent and known-group) validity that met the eligibility criteria were found from 45 publications 181 
[33,34,36,37,43,49,51,53–58,60,62,65,67–71,73–75,77–81,83,85,87–100]. Most reported p values, 182 
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but not effect sizes, and 21 studies had indeterminate results due to not reporting sufficient 183 
information.  184 
Synthesis of results 185 
A synthesis of the results of measurement properties per scale, including quality rating and GRADE 186 
ratings for older adults and people with dementia is provided in table 1.  187 
Apathy specific scales 188 
Apathy Evaluation Scale (AES) 189 
The AES is an 18-item apathy scale based on informant-report; self-report (AES-S) or clinician 190 
assessment. Nine publications regarding the validity or reliability of the AES met the inclusion 191 
criteria. The AES had sufficient content validity, though, like other studies, the evidence for this was 192 
very low. There was moderate evidence for sufficient hypothesis testing for construct validity and  193 
structural validity. The latter result limited the quality of evidence for sufficient internal consistency 194 
(Cronbach’s α=.86 to .95) to moderate also. There was low to moderate evidence for sufficient 195 
reliability, except of the AES-S in people with dementia, where test-retest reliability was insufficient. 196 
The only measurement property that the AES lacked evidence for was measurement error.  197 
Dimensional Apathy Scale (DAS) 198 
The DAS is a 24-item scale, made up of three subscales: executive, emotional and initiation. There is 199 
a self-rated and proxy version, and a shorter proxy version (b-DAS), which retains the three subscales 200 
across just nine items. Five articles investigating the DAS (including b-DAS) met the inclusion criteria 201 
[62,63,74–76]. There was very low evidence of sufficient content validity of the DAS, including b-DAS, 202 
and sufficient test-retest reliability, however this evidence came from a single study of the b-DAS so 203 
conclusions may not be generalizable to the full version. There was moderate to high quality 204 
evidence of sufficient hypothesis testing for construct validity. Structural validity and internal 205 
consistency were not relevant due to this scale’s formative nature, and there was no evidence for 206 
measurement error.  207 
Lille Apathy Rating Scale (LARS) 208 
The LARS was developed to screen for and assess changes in apathy in people with Parkinson’s 209 
Disease, and was originally designed as a clinician-rated scale based on observations and answers 210 
provided in an interview with the participant. Three articles of the LARS met the inclusion criteria 211 
[65,70,83]. There was very low evidence of sufficient content validity, low to moderate evidence of 212 
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sufficient reliability, and high quality evidence for sufficient hypothesis testing for construct validity. 213 
As with the DAS, structural validity and internal consistency were not relevant due to this scale’s 214 
formative nature, and there was no evidence for measurement error. 215 
Dementia Apathy Interview and Rating (DAIR) 216 
The DAIR was developed to assess apathy in people with dementia. One article met the inclusion 217 
criteria [37]. There was very low evidence for inconsistent content validity of the DAIR in older adults, 218 
and low evidence for inconsistent content validity in people with dementia. There was very low to 219 
moderate evidence for sufficient structural validity, and low to moderate evidence of internal 220 
consistency. There was very low evidence for sufficient test-retest reliability, and measurement 221 
error, and low to high quality evidence of sufficient hypothesis testing for construct validity.  222 
Apathy Inventory (AI) 223 
The AI is a 3-domain apathy scale, initially created as a self or informant report via face-to-face 224 
interview and developed for older adults and people with neurological disorders. Three articles of 225 
the AI met the inclusion criteria [34,72,80]. Evidence for content validity and hypothesis testing for 226 
construct validity was inconsistent. There was low evidence for sufficient reliability, and no 227 
conclusive evidence for structural validity or internal consistency.  228 
Apathy Scale (AS) 229 
The AS is a 14-item apathy scale, administered through self-report or informant-report, via interview. 230 
An 11-item paper and pencil version (AS-HC) without sub-questions has also been produced [58]. 231 
Eight articles of the AS met the inclusion criteria [36,58–61,77,90,91]. Despite the high quality 232 
studies, the results regarding structural validity were inconsistent. The AS-HC however had moderate 233 
to low evidence for sufficient structural validity and internal consistency. There was very low 234 
evidence of sufficient content validity and reliability, and low to moderate quality evidence for 235 
sufficient hypothesis testing for construct validity of the AS. There was no conclusive evidence for 236 
internal consistency or measurement error. 237 
Global scales with an apathy subscale  238 
Neuropsychiatric Inventory (NPI) 239 
The NPI is a well-known scale for assessing neuropsychiatric symptoms in people with dementia. 240 
Each subscale of the NPI represents a different symptom, of which apathy is one. Originally designed 241 
as a proxy assessment administered via interview, the NPI now has many variations, including those 242 
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which score the screening or sub-questions, as in the NPI-Alternate (NPI-A), and NPI-Clinician (NPI-C). 243 
The NPI was the most studied scale, with 12 articles meeting the inclusion criteria [51,66,73,79,84–244 
88,94–96]. Content validity of the original NPI apathy subscale was inconsistent, as the emotional 245 
domain was missing from the screening questions. In contrast, the NPI-C had sufficient content 246 
validity. The NPI-A had sufficient structural validity with moderate to very low evidence, and there 247 
was moderate evidence for sufficient internal consistency in people with dementia. There was very 248 
low to low evidence of reliability for the original NPI. The NPI-C had better evidence of reliability, 249 
with low and moderate evidence for sufficient interrater reliability. Hypothesis testing for construct 250 
validity was found to be insufficient for the original NPI, supported by high quality evidence, and for 251 
the NPI-C, evidence was inconsistent. The NPI-A lacked conclusive evidence for hypothesis testing for 252 
construct validity, construct validity, and reliability, whilst the NPI-C and NPI had no conclusive 253 
evidence for structural validity, internal consistency or measurement error of the apathy subscales. 254 
 Behavioral Syndromes Scale for Dementia (BSSD) 255 
The BSSD is a measure of neuropsychiatric symptoms, which contains an apathy subscale consisting 256 
of seven items, for which one publication met the inclusion criteria [43]. There was very low evidence 257 
for sufficient content validity, and inconsistent reliability for face-to-face administration, with 258 
insufficient reliability when administered by telephone. There was very low to moderate evidence of 259 
sufficient hypothesis testing for construct validity, however, results should be interpreted with 260 
caution, as no studies of convergent validity were included. There was no conclusive evidence for the 261 
remaining measurement properties (structural validity, internal consistency, measurement error). 262 
Dysexecutive Questionnaire (DEX) 263 
The DEX was developed as part of the behavioural assessment of the dysexecutive syndrome test 264 
battery. One publication of the DEX met the inclusion criteria [81]. There was inconsistent content 265 
validity, very low evidence for sufficient test-retest reliability and moderate to high quality evidence 266 
of inconsistent hypothesis testing for construct validity. There was no conclusive evidence for the 267 
remaining measurement properties (structural validity, internal consistency, measurement error). 268 
Scales with limited evidence 269 
The AD-RD, IMD and UPDRS all had evidence regarding just one measurement property. The AD-RD 270 
had very low evidence for sufficient test-retest reliability, the IMD had very low to low evidence of 271 
sufficient hypothesis testing for construct validity, and the UPDRS had moderate evidence for 272 
inconsistent hypothesis testing for construct validity.  273 
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There was low to very low evidence of insufficient hypothesis testing for construct validity of the AMI 274 
and whilst there was low evidence for sufficient content validity, it is worth noting that some items 275 
were too conflated with cognition or disinhibition (e.g. “I get things done when they need to be 276 
done, without requiring reminders from others”). 277 
The BMDS, FrsBe, GIP, KBCI and three-item subscale of the GDS (GDS-3a) all had inconsistent content 278 
validity and evidence regarding one other measurement property, although for all cases evidence for 279 
content validity came from researcher ratings only due to absent or indeterminate development and 280 
content validity studies. Both the BMDS and GIP had very low evidence for sufficient reliability and 281 
inconsistent content validity, with only 55% and 44% of items relevant to apathy respectively. Items 282 
and response options of the BMDS created confusing double negatives, and the emotional domain of 283 
apathy was missing from both the BMDS and the GIP. There was very low to low evidence of 284 
sufficient hypothesis testing for construct validity, and in all three versions of the FrSBe rated by 285 
reviewers, none had the required ≥85% of items relevant to apathy, due to items related to personal 286 
hygiene that could be conflated with other impairments. There was moderate to low evidence of 287 
insufficient hypothesis testing for construct validity for the GDS-3a and its inconsistent content 288 
validity was due to inclusion of items too conflated with physical ability, and lack of 289 
comprehensiveness. Despite similar inclusion of items that could be conflated with physical ability 290 
and dysphoria, the six item subscale of the GDS (GDS-6a) had sufficient content validity, as 291 
comprehensiveness and comprehensibility were sufficient. The GDS-6a also had moderate to low 292 
evidence of sufficient hypothesis testing for construct validity. The KBCI had low to very low evidence 293 
of sufficient hypothesis testing for construct validity, and inconsistent content validity due to some 294 
items not being sufficiently relevant to older adults and people with dementia (e.g. “has a lot of get-295 
up-and-go”), and others lacking clear comprehensibility (e.g. “is enterprising”). The results regarding 296 
hypothesis testing for construct validity for the IMD, KBCI, GDS-6a and FrSBe should be interpreted 297 
with caution, as no convergent validity studies met the criteria, and convergent validity is a superior 298 
indicator of construct validity than divergent or known-group validity [27].  299 
Discussion 300 
According to COSMIN guidelines, scales should be recommended if they have sufficient content 301 
validity, at least low-level evidence for sufficient internal consistency, and no high-quality evidence 302 
for insufficient properties. The AES, AMI, AS, DAS, GDS-6a, LARS and NPI-C all had sufficient content 303 
validity in older adults and people with dementia, but the AS, GDS-6a and NPI-C did not have 304 
evidence for sufficient internal consistency. The AES had sufficient internal consistency, though the 305 
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AMI, DAS and LARS were based on a formative model, so internal consistency was not applicable. 306 
Therefore, the AES was the only scale that met the COSMIN criteria for a recommended scale. The 307 
(original) NPI was the only scale to meet COSMIN criteria for a scale that should not be 308 
recommended for use due to high quality evidence for insufficient hypothesis testing for construct 309 
validity. All other scales could potentially be recommended, depending on further research. 310 
However, we argue that the BMDS and GIP are also inappropriate for assessing apathy in older adults 311 
and people with cognitive impairment due to inclusion of too many items that are not relevant and 312 
conflate apathy with cognition.  313 
This review considered both apathy specific scales and apathy subscales derived from a global 314 
assessment, as, though the latter may be designed for screening purposes, as in the NPI, they are 315 
often used in place of full assessments, from which conclusions are drawn: for example, the NPI-316 
apathy subscale has been recommended as a primary outcome measure in clinical trials [101]. 317 
Therefore, it was deemed necessary to assess both types of measures to create a sufficiently 318 
comprehensive review of the evidence for all apathy measures available that may be used to assess 319 
apathy specifically in people with dementia and older adults. It is worth noting that the best quality 320 
apathy measures were all apathy specific scales, rather than those derived from a global measure. 321 
This highlights the importance of apathy specific measures, and may suggest that apathy subscales 322 
derived from global instruments (such as the apathy subscales of the BMDS, BSSD, GDS, IMD, KBCI, 323 
UPDRS, and NPI) should not be used to assess apathy in research or clinical practice, unless followed 324 
by further assessment. However, there is not currently sufficient evidence to make these 325 
conclusions, except for the NPI. The finding that the NPI should not be recommended for assessing 326 
apathy contrasts with its popularity and previous recommendations [20,101]. Our study found that 327 
the NPI apathy subscale had insufficient construct validity and inconsistent content validity, 328 
suggesting it assesses something other than apathy, which expands previous studies which 329 
concluded it had uncertain validity [21]. Whilst this could be due to the low quality of convergent 330 
validity studies, (which were all of inadequate quality), divergent validity studies also supported this 331 
finding, as they showed a high correlation with depression, suggesting the NPI apathy subscale may 332 
conflate apathy with depression. It is important to note that the NPI was designed as a quick 333 
assessment tool for numerous neuropsychiatric symptoms [51], and therefore it is perhaps not 334 
surprising that it does not offer a comprehensive and targeted assessment of apathy specifically. 335 
Therefore, the NPI may be best used as a screening tool, but not as an outcome measure or full 336 
clinical assessment of apathy in older adults or people with cognitive impairment.  337 
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This systematic review applied a wider search strategy and eligibility criteria than previous systematic 338 
reviews [21,22], resulting in the inclusion of a larger number of studies, allowing more evidence to 339 
contribute to the results. Despite the numerous studies of measurement properties identified by this 340 
review, evidence across all measurement properties was often of low or very low quality. In 341 
particular, many development and content validity studies failed to report a systematic process of 342 
how items were produced or refined, did not involve patients, carers, or members of the public, or 343 
did not provide sufficient detail (e.g. even when it was clear that participants were involved in 344 
assessing these properties, it was not clear what aspects [such as items, recall period, instructions, 345 
response options] of the scale participants were consulted about). As such, the included publications 346 
offered little evidence for content validity, with all but two studies result’s being indeterminate, and 347 
no study exceeding doubtful methodological quality. As a result, content validity was largely 348 
determined entirely by reviewer ratings of the scale itself. COSMIN’s reviewer rating technique 349 
ensured a validity rating was possible, even in the presence of insufficient information from the 350 
development and content validity studies. However, this also meant that content validity conclusions 351 
were largely based on very low evidence.  352 
Furthermore, COSMIN guidelines do not advise how to recommend studies of scales based on a 353 
formative model, which discounted three scales (the AMI, DAS and LARS) from the 354 
recommendations. As such, the COSMIN guided recommendations of measures is to be taken with 355 
caution in this study. Regardless of this, no single scale had overwhelmingly superior measurement 356 
properties. The AES, DAS, and LARS all had sufficient content validity, reliability, hypothesis testing 357 
for construct validity, and structural validity and internal consistency where applicable, in people 358 
with dementia and older adults. The LARS was the scale with the best evidence for good 359 
measurement properties, and was the only scale to have high quality evidence for at least one 360 
measurement property in both older adults and people with dementia. However, the LARS may have 361 
less desirable measurement characteristics, as both the self and informant versions involve 362 
interviewer ratings, as well as respondent reports, and was the largest scale found by the review, 363 
with 33 items assessing apathy, so requires more resources and could be burdensome. The AES had 364 
the second most consistent quality evidence across measurement properties, and may have 365 
preferable measurement characteristics, as there are versions that do not require trained raters, and 366 
have fewer items. This is consistent with the recommendation of the AES made by others [20,101]. 367 
The DAS is a promising scale, with good evidence for sufficient measurement properties, with the 368 
exception of reliability. The DAS also has desirable measurement characteristics, as the pencil and 369 
paper based scale does not require interviews, and a short version is available.  370 
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Previous systematic reviews of apathy measures used QUADAS, which was designed only to assess 371 
studies of diagnostic accuracy, and applied these to studies of a variety of measurement properties. 372 
COSMIN on the other hand provides guidance and criteria for assessing the quality of and evidence 373 
for a variety of measurement properties. The high standards set by the COSMIN guidelines and 374 
criteria were however sometimes unattainable. For example in a development study, a lack of 375 
justification of recall period and response options can prevent the results of a development study 376 
being rated as sufficient, yet these aspects represent a small part of the scale, and are rarely 377 
provided by even the best quality studies. As COSMIN quality criteria are binary, it risks over 378 
simplifying the complexities of the true measurement properties and research evidence. Weighted 379 
criteria which place greater emphasis on the items may be preferable for content validity 380 
assessment. An alternative for assessing quality of the remaining measurement properties is that 381 
used by Radakovic and colleagues [21] which rated each result on a scale of four to six possible 382 
scores depending on the measurement property being assessed. However, this does not appear to 383 
have been developed in a systematic way, unlike COSMIN criteria that were created following a 384 
Delphi procedure.  385 
Bias in systematic reviews can be minimised by duplicating all rating activities, however, due to the 386 
large number of studies found by this review, this was impractical in this study. The duplication of 387 
review for a portion of the included studies did however help discussions around what these flaws 388 
may be, limiting subjective decisions. Bias was further minimised by following COSMIN guidelines, 389 
and creating additional criteria where required, informed by PPI when applicable, that could be 390 
followed for all scales. 391 
This review did not restrict the eligibility criteria to people with a diagnosis of dementia or restrict 392 
the age criteria to all adults (instead, choosing that at least 50% should meet the criteria). This meant 393 
that some studies included participants with various diagnoses, such as Parkinson’s Disease and 394 
depression, and included some participants that were younger than 65. Therefore, the results may 395 
be less applicable to the population we set out to study. However, populations do not neatly 396 
segment, and by opting for a more liberal inclusion criteria, we were able to include a wide variety of 397 
studies that may not otherwise have been included. Furthermore, the GRADE approach to 398 
determining the quality of evidence for each measure takes into account the directness of the 399 
results, so evidence that was less direct (i.e. studies in other populations) was marked down 400 
accordingly.  401 
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Apathy is a multidimensional phenomenon, including behavioural, cognitive, social or emotional 402 
domains [1,102], and so it is expected that a comprehensive apathy scales should assess all these 403 
aspects of apathy. For this reason, we did not include studies of scales that only assessed a part of 404 
the apathy construct, such as studies that investigated the separate sub-scales of the LARS and DAS. 405 
It is possible that the best assessment of apathy is through a combination of scales that assess 406 
different individual apathy subdomains, which could be used alongside direct observational methods, 407 
such as accelerometers and other experimental methods, that have recently been used to assess 408 
certain aspects of apathy such reduced goal directed behaviour [103]. Future studies could consider 409 
the evidence for assessing each individual domain of apathy separately. 410 
Conclusion 411 
A number of apathy scales of varying quality are available and have been validated in an older adult 412 
and dementia community-dwelling population. The development of scales was generally poor, due to 413 
lack of transparency and systematic approach in eliciting and refining items and developing the other 414 
measurement aspects such as recall period and response options. Future development of scales 415 
should include a clear and systematic approach at all stages, and involve patients or members of the 416 
public as well as professionals to ensure good content validity. The NPI is not recommended for 417 
apathy assessment, except as a screening tool. The LARS has good measurement properties, so is 418 
recommended for use in use in older adults and people with dementia and MCI studies with 419 
sufficient resources. The DAS, in particular the resource efficient b-DAS, is a promising scale that 420 
requires more research into its properties, particularly reliability. The AES has good measurement 421 
properties and characteristics and is recommended for use in older adults and people with dementia 422 
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Table 1. Overall findings and GRADE 
Measure Content validity Structural Validity Internal Consistency Reliability Measurement error Hypothesis testing for construct validity 
 Summary of findings Quality rating & 
GRADE 

















Summary of findings  
N hypotheses 
confirmed / tested (%) 
Quality rating & 
GRADE 
AD-RD DS: Indeterminate  ?     r=.72 + (Very Low; 
Very Low) 
    
AES DS: Indeterminate 
RR: Sufficient  
 
+ (Very low; 
Very low) 
1 main apathy factor 




.86 to .95 + (Moderate; 
Moderate) 
r/ICC= .72 to .94 + (Moderate; 
Low) 
SEM= 2.7 to 2.9 ? 48/69 (70%) +† (Moderate^; 
Moderate^) 
AI DS: Indeterminate 
RR: Inconsistent  
+/- (Very low; 
Very low) 
  .83 to .96 ? Kappa/ICC = .96 
to .99 
+ (Low; Low)   5/8 (67%) +/-† (Moderate; 
High) 
AMI DS: Indeterminate 
RR: Sufficient  
+ (Very low; 
Very low) 
  .86 *      0/2 (0%) - (Low; Very low) 
AS DS: Indeterminate 
CVS: Indeterminate 
RR: Sufficient  
+ (Very low; 
Very low) 
1 to 3 factors. +/- (High; 
High) 
.69 to .94 ? r/ICC=.78 to .90 + (Very Low; 
Very Low) 
SEM= 2.34 ? 8/12 (67%) +†† (Low^; 
Moderate^) 
BMDS DS: Indeterminate 
RR: Mixed  
+/- (Very low; 
Very low) 
    r=.90 + (Very Low; 
Very Low) 
     
BSSD DS: Indeterminate 
RR: Sufficient 
+ (Very low; 
Very low) 
    ICC= .65 to .85 +/- (Very Low; 
Very Low) 
  1/2 (50%) -† (Very low^; 
Moderate^) 
DAIR DS: Inconsistent 
RR: Inconsistent (OA); 
Sufficient (PwD) 
+/-  (Very low; 
Low) 
1 factor + (Very low; 
Moderate) 
.89 +  (Low; 
Moderate) 




+ (1; 1) 3/4 (75%) + (Low; High) 
DAS DS: Indeterminate 
RR: Sufficient  
+ (Very low; 
Very low) 
3 factors: cognitive; 
behavioural; 
emotional. 
* .81 to .93 * ICC=.84 + (Very Low; 
Very Low) 
  10/13 (77%) + (Moderate; 
High) 
DEX RR: Inconsistent  +/- (Very low; 
Very low)  
    ICC=.93 + (Very Low; 
Very Low) 
  2/4 (50%) +/- (Moderate; 
High) 
FrSBE CVS: Indeterminate 
RR: Inconsistent  
+/- (Very low; 
Very low) 
1 factor ? .80 to .88 ?     4/5 (80%) + (Very low; Low) 




(Very low; Very 
low) 
GDS-6a: + (Very 
low; Very low) 
  .51 ?     GDS-3a: 0/2 (0%) 







Measure Content validity Structural Validity Internal Consistency Reliability Measurement error Hypothesis testing for construct validity 
 Summary of findings Quality rating & 
GRADE 

















Summary of findings  
N hypotheses 
confirmed / tested (%) 




RR: Sufficient  
GIP RR: Inconsistent +/- (Very low; 
Very low) 
    ICC= .72 to .83 + (Very Low; 
Very Low) 
MDD= 2.8 to 3.8 ?    
IMD DS: Indeterminate ?         3/3 (100%) + (Very low; Low) 
KBCI DS: Inconsistent 
RR: Inconsistent 
+/- (Very low; 
Very low) 
        6/7 (86%) + (Low; Very low) 
LARS DS: Indeterminate 
RR: Sufficient 
+ (Very low; 
Very low) 
4 factors * .81 to .87 * r/ Kappa / ICC = 
.93 to 1.00 
+ (Low; 
Moderate) 
  11/13 (85%) + (High; High) 
NPI  DS: Indeterminate 
RR: Inconsistent 
+/- (Very low; 
Very low) 
  .82 to .83 ? r/ rs / ICC= .53 
to .99 
+ (Very Low; 
Low) 
  1/5 (20%) - (High; High) 
NPI-A   1 factor + (Very low; 
Moderate) 
.91 ? (OA);  
+ (Moderate, 
PwD) 
      
NPI-C CVS: Indeterminate 
RR: Sufficient 
+ (Very low; 
Very low) 
    ICC= .87 + (Low; 
Moderate) 
  1/2 (50%) +/- (Moderate; 
High) 
UPDRS DS: Indeterminate 
RR: Inconsistent 
+/- (Very low; 
Very low) 
          
Blank cells indicate no eligible studies or results. 
Quality of measurement property: +, Sufficient; +/-, Inconsistent; -, Insufficient, ? Indeterminate.  
GRADE: Quality of evidence rating in parentheses first indicates quality of evidence for older adults, then people with dementia. 
* not applicable due to formative model. 
†Greater emphasis placed on results of better quality (sub)studies 
†† Greater emphasis placed on studies of convergent validity 
^ Marked down for inconsistency  
Abbreviations: AD-RD, Alzheimer's Disease and Related Dementias Mood Scale; AES Apathy Evaluation Scale; AI, Apathy Inventory; AMI, Apathy Motivation Index; AS, Apathy 
Scale; BMDS, Behavioural and Mood Disturbance Scale; BSSD, Behavioral Syndromes Scale for Dementia; CVS, Content Validity Study; DAIR, Dementia Apathy Interview Rating; 
DAS, Dimensional Apathy Scale; DEX, Dysexecutive Questionnaire; DS, Development Study; FrSBe, Frontal Systems Behavior Scale; GDS-3a, Geriatric Depression Scale 3 item 
apathy subscale; GDS-6a, Geriatric Depression Scale 6 item apathy subscale; GIP, Behavioral Rating Scale for Psychogeriatric Inpatients; IMD, Index of Mental Decline; KBCI, Key 
Behaviors Change Inventory; LARS, Lille Apathy Rating Scale; MDS-UPDRS, Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale; NPI, 
20 
 
Neuropsychiatric Inventory; NPI-A, Neuropsychiatric Inventory Alternative; NPI-C, Neuropsychiatric Inventory Clinician; OA, Older Adults; PwD, People with Dementia and MCI; 





MEDLINE search strategy. 3 
 Search terms 
1 (instrumentation or methods).sh. 
2 (Validation Studies or Comparative Study).pt. 
3 exp Psychometrics/ 
4 psychometr*.ti,ab. 
5 (clinimetr* or clinometr*).tw. 
6 exp "Outcome Assessment (Health Care)"/ 
7 outcome assessment.ti,ab. 
8 outcome measure*.tw. 
9 exp Observer Variation/ 
10 observer variation.ti,ab. 
11 exp Health Status Indicators/ 
12 exp "Reproducibility of Results"/ 
13 reproducib*.ti,ab. 
14 exp Discriminant Analysis/ 
15 (reliab* or unreliab* or valid* or coefficient or homogeneity or homogeneous or "internal consistency").ti,ab. 
16 (cronbach* and (alpha or alphas)).ti,ab. 
17 (item and (correlation* or selection* or reduction*)).ti,ab. 
18 (agreement or precision or imprecision or "precise values" or test-retest).ti,ab. 
19 (test and retest).ti,ab. 
20 (reliab* and (test or retest)).ti,ab. 
21 (stability or interrater or inter-rater or intrarater or intra-rater or intertester or inter-tester or intratester or 
intra-tester or interobserver or inter-observer or intraobserver or intra-observer or intertechnician or inter-
technician or intratechnician or intra-technician or interexaminer or inter-examiner or intraexaminer or intra-
examiner or interassay or inter-assay or intraassay or intra-assay or interindividual or inter-individual or 
intraindividual or intra-individual or interparticipant or inter-participant or intraparticipant or intra-participant 
or kappa or kappa's or kappas or repeatab*).ti,ab. 
22 ((replicab* or repeated) and (measure or measures or findings or result or results or test or tests)).ti,ab. 
23 (generaliza* or generalisa* or concordance).ti,ab. 
24 (intraclass and correlation*).ti,ab. 
25 (discriminative or "known group" or factor analysis or factor analyses or dimension* or subscale*).ti,ab. 
26 (multitrait and scaling and (analysis or analyses)).ti,ab. 
27 (item discriminant or interscale correlation* or error or errors or "individual variability").ti,ab. 
28 (variability and (analysis or values)).ti,ab. 
29 (uncertainty and (measurement or measuring)).ti,ab. 
30 ("standard error of measurement" or sensitiv* or responsive*).ti,ab. 
31 ((minimal or minimally or clinical or clinically) and (important or significant or detectable) and (change or 
difference)).ti,ab. 
32 (small* and (real or detectable) and (change or difference)).ti,ab. 
33 (meaningful change or "ceiling effect" or "floor effect" or "Item response model" or IRT or Rasch or "Differential 
item functioning" or DIF or "computer adaptive testing" or "item bank" or "cross-cultural equivalence").ti,ab. 
22 
 
34 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 
or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 
35 exp APATHY/ 
36 apath*.mp 
37 amotivat*.ti,ab. 
38 diminished motivation.ti,ab. 
39 diminished interest.ti,ab. 
40 lack of interest.ti,ab. 
41 diminished initiat*.ti,ab. 
42 lack of initiat*.ti,ab. 
43 lack of motivation.ti,ab. 
44 emotional* blunt*.ti,ab. 
45 abulia.ti,ab. 
46 anhedonia.ti,ab. 
47 exp Anhedonia / 
48 frontal symptom*.ti,ab. 




53 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 
54 34 and 53 
55 limit 54 to "all adult (19 plus years)" 
 4 
  5 
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Data Extraction Table 6 
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COSMIN Risk of Bias 9 
 10 
Category Boxes of the COSMIN Risk of Bias Checklist 
Content Validity Box 1. PROM development 
Box 2. Content validity 
Internal Structure Box 3. Structural validity 
Box 4. Internal consistency 
Box 5. Cross-cultural validity 
Remaining measurement 
properties 
Box 6. Reliability 
Box 7. Measurement error 
Box 8. Criterion validity 
Box 9. Hypothesis testing for construct validity 
Box 10. Responsiveness 
Adapted with permission from Mokkink et al.[27] 11 
Each risk of bias checklist box is to be completed for each study that assesses that measurement 12 
property. Boxes 1 is to be completed for original development studies, whereas box 2 is to be 13 
completed for any additional content validity studies, or studies developing an established measure 14 
in a different population. Box 8 will not be completed for any study in this systematic review, as no 15 
gold standard measure of apathy exists. For details of how risk of bias is assessed for each 16 
measurement property, see Mokkink et al [27]. 17 
Full guidelines followed for this review are found in the comprehensive COSMIN user manual version 18 
1.0 dated February 2018 downloaded from: https://www.cosmin.nl/wp-content/uploads/COSMIN-19 
syst-review-for-PROMs-manual_version-1_feb-2018-1.pdf  and the content validity user manual 20 








Supplementary Tables 27 
Table S.1. Overview of measures 28 
Measure N of publications 
meeting criteria† 
Original intended…  
a) construct 
b) target population  
c) context 
Version Measurement characteristics (refers only to the apathy component of the scale) 
Mode of administration & other 
administration information 
Recall Period Number 
of items  
Scoring and Response options* 
AD-RD 
[40,41]  
1 [40]  a) Mood 
b) Moderate to severe AD 
c) Research or clinical  
n/a Interviewer-judgement, informed 
by observation and patient and 
carer interview 









b) People with various clinical disorders 
or apathy, (with MMSE over 10 for 
patient reported version) 
c) Clinical 
AES-C Clinician-rated based on semi-
structured interview with patient 
and observations. Bachelor level 
raters can conduct with 4-6 hours 
experience. 
10 to 20 minutes to administer 
4 weeks 18  Items rated on Likert scale (1 to 4; all options 
described), and quantifiable items rated 1 to 4 based 0, 
1-2, 2-3, 3 or more quantifiable instances. Requires 
verbal or nonverbal evidence of intensity. 
Total score is sum of item scores. Range 18 to 72. 
AES-I Informant-report via paper and 
pencil 
10 to 20 minutes to administer. 
4 weeks 18 Likert scale (1 to 4; all options described). 
Total score is sum of item scores. 
Range 18 to 72. 
AES-I (16 item 
versions) 
Informant-report via paper and 
pencil 
4 weeks 16 Likert scale (1 to 4; all options described). 
Total score is sum of item scores. Range 18 to 64 
AES-S Self-report via interview 
(recommended) or paper and 
pencil 
10 to 20 minutes to administer 
4 weeks 18 Likert scale (1 to 4; all options described). 
Total score is sum of item scores. Range 18 to 72. 
AES-12PD Self-report  4 weeks 12 Likert scale (1 to 4; all options described). 




3 [34,72,80] a) Apathy 
b) Older adults with brain disorders 
c) Clinical 
AI-C Clinician opinion based on 
observations, and participant and 
informant answers to the AI when 
available. 
At least 20 minutes of observation 
Since beginning 




3 Likert scale (0 to 4; 3 options described) 
Total score is the sum of item scores. Range 0 to 12 
30 
 
Measure N of publications 
meeting criteria† 
Original intended…  
a) construct 
b) target population  
c) context 
Version Measurement characteristics (refers only to the apathy component of the scale) 
Mode of administration & other 
administration information 
Recall Period Number 
of items  
Scoring and Response options* 
time period e.g. 
last four weeks. 
AI-I Informant-report via interview Since beginning 




3 Screening questions: (Yes=0 or No) with follow-up 
questions rated on Likert scale (Frequency: 1 to 4; 
Severity: 1 to 3; all options described )  
Item score is Frequency x Severity. Range 0 to 12. 
Total score is the sum of items scores. Range 0 to 36. 
AI-S Self-report via interview Since beginning 




3 Screening questions: 0=“Yes”; “No” with follow up 
question rated on a visual scale (1 to 12; end-points 
described).  
Total score is the sum of item scores. Range 0 to 36. 
AMI [35] 1 [67] a) Apathy 
b) Healthy adults 
c) Research 
n/a Self-report via paper & pencil 2 weeks 18 Likert Scale (0 to 4; all options described). 
Total score is sum of item scores. Range 0 to 72. 










AS-HC Self-report via paper and pencil 4 weeks 11 Likert scale: (0 to 3; all options described). Total score 
is sum of item scores. Range 0 to 33 
AS-I Informant report via interview 
~ 10 minutes to administer 
4 weeks 14 Likert Scale (0 to 3; all options described). Total score is 
sum of item scores. Range 0 to 42. 
AS-S Self-report via interview  4 weeks 14 Likert Scale (0 to 3; all options described). Total score is 
sum of item scores. Range 0 to 42. 
AS-S (13 item 
version) 
Self-report via interview 4 weeks 13 Likert scale: (0 to 3; all options described). Total score 
is sum of item scores. Range 0 to 39 
BMDS [42]  1 [42] a) Neuropsychiatric symptoms 
(behaviour & mood disturbances) 
b) Dementia 
c) Research 
n/a Informant report via interview - 11 Likert scale (0 to 4; all options described) 
Total score is sum of item scores. Range 0 to 44. 
BSSD [43]  1 [43] a) Neuropsychiatric symptoms 
(behavioural syndromes in AD) 
b) AD 
c) Clinical 
n/a Clinician-judgement based on 
information from interview with 
informant and informed by clinician 
observations 
1 week 7 Likert scale (0 to 6; all options described). 
Total score is not specified but presumable sum of item 
scores. 
DAIR [37]  1 [37] a) Apathy 
b) Dementia (mild-moderate) 
c) Research and clinical 
n/a Interviewer-judgement based on 
informant reports. In person or over 
the phone. 
1 month 16 Main items rated on Likert scale by informant: (0 to 3; 
all options described) with follow-up questions to 
31 
 
Measure N of publications 
meeting criteria† 
Original intended…  
a) construct 
b) target population  
c) context 
Version Measurement characteristics (refers only to the apathy component of the scale) 
Mode of administration & other 
administration information 
Recall Period Number 
of items  
Scoring and Response options* 
~ 30 minutes administration time determine if this was a change in apathy rated by the 
interviewer (no change; increase; decrease)   
Total score is sum of all items reflecting a change (more 
apathetic), divided by the number of items completed. 
DAS [38]  5 [62,63,74–76] a) Apathy 
b) Neurodegenerative diseases 
specifically with motor disability 
c) Research and clinical 
DAS-I Informant reported via online or 
paper and pencil 
~ 5 minutes to administer 
1 month 24  
(8 per 
subscale) 
Likert scale (0 to 3; all options described).  
‘Executive’, ‘Initiation’ and ‘Emotional’ subscales are 
scored by summing all items in sub-scale. Range 0 to 
24. 
Total score is the sum of the subscale scores. Range 0 
to 72. 
DAS-S Self-reported via online or paper 
and pencil 
~ 5 minutes to administer 
1 month 24  
(8 per 
subscale) 
Likert scale (0 to 3; all options described).  
 ‘Executive’, ‘Initiation’ and ‘Emotional’ subscales are 
scored by summing all items in sub-scale. Range 0 to 
24. 
Total score is the sum of the subscale scores. Range 0 
to 72. 
b-DAS Informant reported via online or 
paper and pencil 
>5 minutes to administer 




Likert scale (0 to 3; all options described).  
‘Executive’, ‘Initiation’ and ‘Emotional’ subscales are 
scored by summing all items in sub-scale. Range 0 to 9. 
Total score is the sum of the subscale scores. Range 0 
to 27. 
(an awareness deficit rating is also present but not 
included in the total score) 
DEX [44]  ̂ 1 [81]  - - - - - - 






FrSBe-14a - - 14 - 
FrSBe-11a - - 11 - 






b) Older adults 
c) Clinical screening  
GDS-3a  Self-reported via paper and pencil 
(interviewer administered if 
required) 
1 week 3 Responses (Yes/No) that indicate depression are 
scored 1. 
Total score is sum of items. Range 0 to 3 
GDS-6a Self-reported via paper and pencil 
(interviewer administered if 
required) 
1 week 6 Responses (Yes/No) that indicate depression are 
scored 1. 
Total score is sum of items. Range 0 to 3 
32 
 
Measure N of publications 
meeting criteria† 
Original intended…  
a) construct 
b) target population  
c) context 
Version Measurement characteristics (refers only to the apathy component of the scale) 
Mode of administration & other 
administration information 
Recall Period Number 
of items  
Scoring and Response options* 







GIP-subscale - - - - 




Observation by health professional 2 to 3 weeks 9 Likert scale (options not described) 
IMD [49]  1 
[49] 
a) ‘Mental decline’ or  ‘impairment’ 
b) Older adults, particularly with 
dementia 
c) Research. (Possibly also for clinical 
evaluation of progression but 
should not be used for diagnosis) 
n/a Informant reported Not reported 
 
3 Items are rated using categories that are associated 
with weighted scores depending on the item.  
0=“Absent”; 2/3=“Mild-moderate / discontinuous 
symptoms”; 4/5/6=“Severe / continuous symptoms” 






a) Behaviour change 
b) Traumatic Brain Injury 
c) Clinical and research 
 
KBCI-8a Informant reported via paper and 
pencil 
Not reported 8  Likert scale (all options described) Total score is the 
sum item scores but the scores attributed to the Likert 
scale and therefore the range is unspecified. 
KBCI-10a Informant reported via paper and 
pencil 
Not reported 10 Likert scale (all options described) Total score is the 
sum item scores but the scores attributed to the Likert 






b) Parkinson’s Disease 
c) Clinical and research? 
LARS-C Interviewer-judgement informed by 
patient self-report and interviewer 
observations during the interview 
with the patient 
 
4 weeks 33 Four items are based on 3 or 5 point Likert scales (all 
options described) 
For the remaining items, patient responses are 
categorised by the interviewer as 1 or -1 (all options 
described). Items are scored 0 if they are rated ‘N/A’ or 
the interviewer was not able to categorise the reply. 
Total score is the sum item scores. Range -36 to 36. 
LARS-I Interviewer-judgement informed by 
informant-responses during the 
interview with the informant 
4 weeks 33 Five items are based on 3 or 5 point Likert scales (all 
options described) 
For the remaining items, informant responses are 
categorised by the interviewer as 1 or -1 (all options 
described). Items are scored 0 if they are rated ‘N/A’ or 
the interviewer was not able to categorise the reply. 
Total score is the sum item scores. Range -36 to 36. 






a) Neuropsychiatric symptoms 
b) Dementia 
c) Research and clinical 






Screening question (Yes=0; No), with follow-up 
questions using Likert scales, regarding severity (1 to 3; 
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Measure N of publications 
meeting criteria† 
Original intended…  
a) construct 
b) target population  
c) context 
Version Measurement characteristics (refers only to the apathy component of the scale) 
Mode of administration & other 
administration information 
Recall Period Number 
of items  









all options described) and frequency (1 to 4; all options 
described). 
Total score is Frequency x Severity 
(a distress rating is also present but not included in 
total score) 





- Each item is rated for frequency on the same Likert 
scale as the original NPI.  
Total score is the sum of frequency scores. 
(Severity is also rated for the overall domain as per the 




Clinician-judgement, informed by 
information from the NPI with an 
informant and patient as well as 
other relevant information about 
the patient. Clinicians must have a 
minimum of two years’ experience 






Each item is scored individually by informants, 
employing the Likert method as the original NPI, 
regarding frequency, severity and distress. Total score 
is the summation of frequency and severity item 
scores. 
A clinical rating method is also required: Each item is 
also rated by a clinician based on their clinical 
impressions, informed by the interview with the 
patient and informant, clinical notes and other carers, 
rated on Likert scale (0 to 3). Total score is the sum of 
these clinician rated item scores. 
Two separate total scores are obtained: one from the 
informant, one from the clinician. 
UPDRS [52]  ̂ 4 
[97–100] 
 
- UPRDS - - 1 Likert scale (0 to 4; all options described). No total 
score calculation required as only 1 item present. 
MDS-UPDRS Rater-judgement informed by 
interview with patient and / or 
informant 
1 week 1 Likert scale (0 to 4; all options described). No total 
score calculation required as only 1 item present. 
† Number does not include development article where development article did not meet the inclusion criteria, even if it was later assessed for purposes of content validity 29 
* Reverse coding is not included here 30 
^ Unable to obtain development article for rating  31 
-  Unable to obtain information 32 
34 
 
Abbreviations: AD-RD, Alzheimer's Disease and Related Dementias Mood Scale; AES Apathy Evaluation Scale; AES-12PD, Apathy Evaluation Scale for Parkinson Disease; AES-C, Apathy 33 
Evaluation Scale Clinician; AES-I, Apathy Evaluation Scale Informant; AES-S, Apathy Evaluation Scale Self; AI, Apathy Inventory; AI-C, Apathy Inventory Clinician; AI-I, Apathy Inventory 34 
Informant; AI-S, Apathy Inventory Self; AMI, Apathy Motivation Index; AS, Apathy Scale; AS-HC, Apathy Scale Home Care; AS-I, Apathy Scale Informant; AS-S, Apathy Scale Self; b-DAS, brief-35 
Dimensional Apathy Scale; BMDS, Behavioural and Mood Disturbance Scale; BSSD, Behavioral Syndromes Scale for Dementia; DAIR, Dementia Apathy Interview Rating; DAS, Dimensional 36 
Apathy Scale; DAS-I, Dimensional Apathy Scale Informant; DAS-S, Dimensional Apathy Scale Self; DEX, Dysexecutive Questionnaire; FrSBe, Frontal Systems Behavior Scale; FrSBe-6a, Frontal 37 
Systems Behavior Scale 6-item apathy subscale; FrSBe-11a, Frontal Systems Behavior Scale 11-item apathy subscale; FrSBe-14a, Frontal Systems Behavior Scale 14-item apathy subscale; 38 
GDS, Geriatric Depression Scale apathy; GIP, Behavioral Rating Scale for Psychogeriatric Inpatients; IMD, Index of Mental Decline; KBCI, Key Behaviors Change Inventory; KBCI-8a, Key 39 
Behaviors Change Inventory 8 item apathy subscale; KBCI-10a, Key Behaviors Change Inventory 10 item apathy subscale; LARS, Lille Apathy Rating Scale; MDS-UPDRS, Movement Disorder 40 
Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale; NPI, Neuropsychiatric Inventory; NPI-A, Neuropsychiatric Inventory Alternative; NPI-C, Neuropsychiatric Inventory 41 
Clinician; UPDRS, Unified Parkinson’s Disease Rating Scale  42 
 43 
Table S.2. Overview of studies 44 




Residential status N Population 
(N of each subgroup, or % 
where N not possible to 
calculate) 









Apathy score  
Mean (SD, range)  
[40]  AD-RD  English  ̂ Reliability (test-retest). "Approximately half 




N=39 nr 79.33 (9.22 ; 
55 to 96)  
49% 17.21 (5.98, 3 to 
24) 
AD-RD apathy: 10.57 
(3.88) 
Development (pilot study) "Conducted in a 
dementia-specific 






N=45 Cognitive Impairment 
(type not specified)  
79.00 (8.37; 
61 to 94) 








elicitation via interviews)  
Nursing home and 
day care. No 
confirmation from 
N=39 Carers of people with 
moderate to severe AD: 
Formal carers (N=19).  
Nursing 
home: 85 (nr, 
nr) 
25% nr nr 
35 
 




Residential status N Population 
(N of each subgroup, or % 
where N not possible to 
calculate) 









Apathy score  




Informal carers (N=20). 
 
(Number of people with 
AD that were being 
interviewed about =20) 











Structural validity; Internal 
consistency; Reliability 
(interrater & test-retest). 
Hypothesis testing 







N=92 Major depressive disorder:  
Current Depression (CD; 
N=31) 
Remitted Depression (RD; 
N=30)  











nr 2 means for each group 











nr Structural validity;  
Hypothesis Testing 
(convergent & divergent).  
Community-dwelling 
(95.8%) and nursing 
home residents 
(4.2%). 
N=121 Dementia:  
AD (55.2%);  
MD (AD-DLB, 14.3%; AD-
VaD, 5.7%);  
DLB (9.5%);  
VaD (5.7%),  
FtD (4.8%);  
‘other dementia’ (4.8%). 




English  ̂ Structural validity; Internal 
consistency; Hypotheses 
testing (divergent & 
known groups). 
Outpatient and 





N=75 MCI (N=57);  
Cognitively normal (Ctrl 
N=18) 
MCI: 74.5 
(8.6, 53 to 86) 
Ctrl: 75.4 (6.0, 
63 to 84)  
Total: 74.7 




MCI: 27.3 (1.9, 
23 to 30) 
Ctrl: 29.4 (0.8, 28 
to 30)  
Total: 27.8 (1.9, 
23 to 30) 
AES-C: 
MCI: 60.9±7.7 (39–72) 
Ctrl: 68.4±4.3 (55–72) 
Total: 62.7±7.7 (39–72) 
AES-I:  
MCI: 61.1 (8.0, 42 to 72) 
Ctrl: 68.3 (4.5, 58 to 72)  
Total: 62.8 (7.9, 42 to 72) 
36 
 




Residential status N Population 
(N of each subgroup, or % 
where N not possible to 
calculate) 









Apathy score  
Mean (SD, range)  
AES-S:  
MCI: 63.3 (8.0, 40 to 72) 
Ctrl: 67.2 (4.2, 56 to 72) 






English  ̂ Development (item 
elicitation and pilot); 




(divergent & known 
groups).  
Community-dwelling N=123  
(N=40 for 
pilot) 
(n/a for item 
elicitation) 
Mixed sample:  
Healthy controls (Ctrl, 
N=31);  
Probable AD (N=21);  
Major Depression (Dep; 
N=30);  
Left Hemisphere Stroke 
(LHS, N=19);  




















Total: 40.65%  
Ctrl: 29.1 (1.1, nr) 
AD: 19.1 (6.5, nr)  
Dep: 28.0 (1.7, 
nr) 
LHS: 25.0 (4.6, 
nr)  
RHS: 26.9 (2.3, 
nr)   
AES-C: 
reported separately for 
the 2 clinician ratings: 
Ctrl: 26 (6.2, nr); 25.8 
(5.8, nr) 
AD: 44.4 (11.1, nr); 45.2 
(11.7, nr);  
Dep: 40.5 (9.7, nr); 36.6 
(8.3, nr) 
LHS: 31.9 (9.6, nr); 32.0 
(11.7, nr) 
RHS: 34.7 (7.3, nr); 35.4 
(9.6, nr) 
AES-I: 
Ctrl: 26.3 (7.5, nr) 
AD: 49.1 (9.9, nr) 
Dep: 41.7 (15.0, nr) 
LHS: 28.1 (6.9, nr) 
RHS: 35.4 (10.9, nr) 
AES-S: 
Ctrl: 28.1 (6.4, nr) 
AD: 35.5 (8.1, nr) 
Dep: 38.7 (9.8, nr) 
LHS: 32.2 (8.6, nr) 
RHS: 31.6 (6.7, nr) 
[71] AES-I; 
AES-I-16 







Dementia 83.19 (8.32, 
59 to 100, 
N=99) 
29% 16.35 (7.60, 0 to 
29, N=65) 








Residential status N Population 
(N of each subgroup, or % 
where N not possible to 
calculate) 









Apathy score  
Mean (SD, range)  
[56]  AES-I; AES-
S 






















disease and cognitive 
impairment: 
MCS (N=222. AES-I N=192. 
AES-S N=209) with 
subgroups of subjective 
cognitive decline (SCD, 
N=97) and MCI (N=125). 
Parkinson's Symptoms (PS, 
N=88. AES-I N=76. AES-S 
N=88), with subgroups of 
PD (PD, N=71); Parkinson’s 
Disease Dementia or 
Dementia with Lewy 
Bodies (PDD-DLB, N=17).  
Ctrl (N=201. AES-I N=135; 
AES-S N=199) 
MCS: 70 (6) 
MCI: 71 (6) 
PD: 67 (9) 
PDD-DLB: 74 
(6) Ctrl: 75 (5) 







median (Q1 to 
Q3) 
 
MCS: 29 (27 to 
29) 
MCI: 27 (26 to 
28) 
PD: 29 (27 to 30) 
PDD-DLB: 23 (20 
to 24)  
Ctrl: 29 (28 to 30) 
Total: 29 (27 to 
29) 
AES-I 
MCS: 36.2 (10.6, nr) 
PS: 52.3 (11.4, nr)) 
Ctrl: 28.7 (8.2, nr) 
Total: 36.6 (12.9, nr) 
AES-S 
MCS: 32.6 (8.8 , nr) 
PS: 53.3 (10.6, nr) 
Ctrl: 28.0 (5.7, nr) 
Total: 34.2 (11.9, nr) 
[89] AES I; AES-
S 
Italian Hypothesis Testing 
(divergent). 






N=48 Parkinson’s Disease (PD) 72.21 (9.01, 
nr) 
64.58%* 22.83 (4.71,nr) AES-I: 45.14 (13.09, nr) 
AES-S: 49.85 (10.37, nr) 
[57] AES-S German  ̂ Structural validity; Internal 
consistency; Hypothesis 
testing (convergent & 
divergent).  




N=665  Parkinson’s Disease 
Sub-sample of PD 
excluding comorbidities of 







PD: 67.9%  
PDexclDd: 
66.52%   
PD: 27.94 (2.23) 
PDexclDd: 28.47 
(1.58) 
PD: 30.63 (9.49) 
PDexclDd: 27.96 (7.59) 
[78] AES-12PD German Internal consistency; 
Hypothesis testing 
(convergent & divergent) 
Data taken from a 







(Sample split for analyses: 
Sample 1: N=170; Sample 
2: N=169) 
Subsample of PDDd: N=42 
Sample 1: 68 
(nr, nr)  






median (Q1 to 
Q3) 
Samples 1&2: 29 
(nr, nr) 
median (Q1 to Q3) 
AES: 
Samples 1&2: 27.0 (nr) 
AES-12PD: 
Sample 1: 17.0 (nr) 
Sample 2: 18.0 (nr) 
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Residential status N Population 
(N of each subgroup, or % 
where N not possible to 
calculate) 









Apathy score  
Mean (SD, range)  
[34] AI French  ̂ Development (item 
elicitation) 
n/a no participants. n/a n/a n/a n/a n/a n/a 
Internal consistency; 
Reliability (test-retest & 
interrater), hypothesis 
testing (convergent, 













or cognitive Impairment:  
AD (N=60);  
PD without dementia 
(N=12),  
MCI (N=24) 
Ctrl (N=19).  















AD: 22.55 (3.98, 
nr) 
PD: 27.2 (3.5, nr) 
MCI: 28.21 (1.06, 
nr) 
Ctrl: 29 (nr, nr)  
AI-I   
AD: 9.20 (10.4, nr)  
PD: 8.00 (6.0, nr)   
MCI: 4.21 (8.6, nr)   
Ctrl: 1.05 (2.0, nr)   
AI-S 
AD: 3.74 (5.9, nr)  
PDexlD: 9.10 (8.3, nr) 
MCI: 2.47 (3.8, nr) 
Ctrl: 1.51 (2.9, nr) 




nr, but confirmed all 
community via 
correspondence 
N=175. Mixed sample:  
AD (N=55) 
MCI (N=35)  
Dep (N=32)  
PD (N=30) 
Ctrl (N=23)  
AD: 78.4 (nr, 
61 to 95) 
MCI: 69.1 (nr, 
60 to 86) 
Dep: 69.7 (nr, 
55 to 88) 
PD: 66.5 (nr, 
42 to 84);  
Ctrl: 67.3 (nr, 
52 to 88) 
Total: 71.45* 
Total: 34.3% AD: 16.8 (nr, 0 to 
27) 
PD: 26.9 (nr, 18 
to 20) 
Dep: 24.3 (nr, 16 
to 30)  
MCI: 25.4 (nr, 22 
to 27) 
Ctrl: 29.1 (nr, 28 
to 30) 
Total: 23.28* 
AI scores nr. Apathy 
'diagnosis' according to 






[72] AI-C French Internal consistency; 
Hypothesis testing 
(convergent). 









AD (N=17); MCI (N=12); 
MD (N=8); VaD (N=2); DLB 
(N=1) 
77.5 (8.01, nr) 45%* 20 (6.73, nr) nr 
39 
 




Residential status N Population 
(N of each subgroup, or % 
where N not possible to 
calculate) 









Apathy score  
Mean (SD, range)  
[67] AMI English Internal consistency; 
Hypothesis testing 
(convergent) 










Ctrl: 66.1 (8.5, 
nr) 





PD: 89.4 (9.0, nr) 
All at least over 
50 
Ctrl: nr 
PD: 35.29% apathetic in 
at least one AMI subscale  






N=11 Dementia:  
AD (N=8);  
FtD (N=3);  
AD: 78.3 (4.7) 










22.8 (8.4, 12 to 39) 
Hypothesis testing 
(convergent & divergent) 
Population random 










English  ̂ Structural validity; Internal 
consistency. 
nr, but confirmed all 
community via 
correspondence 




66.70% (N=7) 29.14 
(0.69, nr)  
10.99 (6.26, nr) 
[36] AS-S English  ̂ Development n/a, no participants n/a n/a  n/a n/a n/a n/a 
Internal consistency; 
Reliability (interrater & 
test-retest); Hypothesis 
testing (known groups)   









grouped into sub-samples 
based on apathy and 
depression scores: 
PD, no apathy, no 
depression (PD; N=16) 
PD, with apathy, no 
depression, (PDa; N=6) 
PD, no apathy, with 
depression, (PDd; N=13) 
PD: 67 (9, nr)  
PDa: 69 (7, 
nr) 
PDd: 62 (12, 
nr) 
PDa&d: 69 (8, 
nr) Total: 
66.54 (9.26)*  
PD: 50% 
PDa: 66% 
PDd: 57%  
Pa&d: 73% 
Total: 62%*  
PD: 28.7 (1.1, nr) 
PDa: 28.3 (1.2, 
nr) 
PDd: 26.3 (4.6, 
nr) 




PD: 7.3 (2.8, nr) 
PDa: 17.1 (4.0, nr) 
PDd: 10.0 (2.0, nr) 
PDa&d: 19.5 (3.3, nr) 
Total =12.84 (2.87)* 
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Residential status N Population 
(N of each subgroup, or % 
where N not possible to 
calculate) 









Apathy score  
Mean (SD, range)  
PD, with depression and 
apathy (PDa&d; N=15) 
[58] AS-S 
AS-HC 






N=122 Parkinson's Disease 70.9 (7.8, nr) 49.2% nr AS-S: 26.6 (8.12, nr) 
AS-S-11: 21.3 (6.88, nr) 
[60] AS-S Norwegian Structural validity; Internal 
consistency; Hypothesis 
testing (divergent). 






N=194 Parkinson’s Disease 67.9 (9.0, nr) 59.3%  27.8 (2.3, nr) 15.5 (4.6, 4 to 29) 
(median =15.0).  















Parkinson’s Disease  67.5 (10.2, nr) 65.5%* Short Portable 
Mental Status 
Questionnaire of 
Pfeiffer: 1.3 (1.6, 
nr). 
12.7 (7.1, nr)  






















PD: 11.59 (5.36,nr)  
HC: 9.21 (4.67,nr) 
[91] AS-S Spanish Internal consistency; 
Hypothesis testing 
(convergent; divergent) 
nr. Unknown to 
corresponding 
author as data not 
collected. 
N=60 Advanced Parkinson’s 
Disease 
68.02 (7.43; 
50 to 81) 
60.70% nr 11.55 (6.49, 1 to 24) 
 
[42]  BMDS English
^ Development (item 
elicitation) 
n/a, no participants n/a n/a  n/a n/a n/a n/a 
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Residential status N Population 
(N of each subgroup, or % 
where N not possible to 
calculate) 









Apathy score  
Mean (SD, range)  
Reliability (test-retest). nr, but scale 
designed to assess 






Dementia 76 (nr, 59 to 
87) 
23.68% nr 24.95 (9.30, nr) 
[43]  BSSD English Development (item 
elicitation and pilot) 
Item elicitation: n/a 
no participants 
Pilot: nr 
nr nr nr nr nr nr 
Internal consistency;  
Reliability (interrater & 
test-retest); Hypothesis 
Testing (divergent & 
known groups) 









N=83 to 97; 
reliability: 
N=20 to 21) 
Alzheimer’s Disease 72.1 (9.8, 45 
to 93) 
35% male Modified MMSE: 
26.2 (13.8, 0 to 
52) 
Global apathy / 
indifference =31.1% 
absent; 50.0% minimal to 
mild; 18.8% moderate to 
severe. 
raw scores nr. 
[37]  DAIR English  ̂ Development (item 
elicitation and pilot);  
nr nr Mixed sample: People with 
AD, their carers and clinical 
researchers. 
nr nr nr nr 
Structural validity; Internal 
consistency; Hypothesis 
testing (convergent & 
divergent) 
nr 
Designed to assess 
people living in 
environments 
whose daily activities 









N=100 Alzheimer’s Disease 75.00 (8.48; 
52 to 92) 




1.19 (0.69, 0 to 3) 
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Residential status N Population 
(N of each subgroup, or % 
where N not possible to 
calculate) 









Apathy score  





Development study (item 
elicitation) 
n/a no participants 
involved in item 
elicitation 
n/a n/a n/a n/a n/a n/a 
[75] DAS English  ̂ Internal consistency; 
Hypothesis testing 
(convergent; divergent)  







without dementia and 
healthy controls: 
PD (N=34)  
Ctrl (N=34) 
PD: 68.2 (9.2, 
nr) 
Ctrl: 66.1 (9.2, 
nr)  
44.12% nr PD: 25.8 (8.7, nr) 
Ctrl: 21.2 (7.0, nr) 
DAS-I   
N=60 
 




nr for this 
sub-sample 
nr for this sub-
sample 
nr PD: 25.1 (12.8, nr) 
Ctrl: 19.7 (9.5, nr) 
[74] DAS English  ̂ Internal Consistency; 
Hypothesis testing 
(convergent & divergent) 
Community-dwelling N=157* DAS-I 
Alzheimer’s Disease and 
controls 
AD (N=102)  
Ctrl (N=55) 
AD: 78.2 (8.5, 
nr) 82.4% 
aged 65 and 
over. 
Ctrl: 75.0 (6.1, 
nr) 
AD: 51.0%* 
Ctrl: 50.9%*  
AD (N=80): 22.0 
(5.3, nr)  
Ctrl: nr 
nr, but AES: 
AD: 51.7 (11.5, nr) 
Ctrl: 28.8 (5.2, nr) 
DAS-S 
AD (N=55, sub-sample of 
those above) 
Ctrl (same as above, n=55) 
AD: 77.5 (7.9, 
nr) 




nr nr, but AES:   
AD: 38.9 (9.0, nr) 
[62] DAS-S Italian Structural validity, Internal 
consistency, Hypothesis 
testing (convergent, 
divergent & known 
groups) 




N=207  Parkinson’s Disease and 
controls 






PD: 60.75%* PD: 27.63 
(2.09,nr) 
PD: 25.25 (12.76,nr) 
(Median (skewness)=23 
(1.254)) 
Ctrl: 21.29 (8.35,nr)  
[63] bDAS English Structural validity AD: Community-
dwelling 












AD: (N=80): 22.0 
(5.3, nr)  
ALS: nr 
Total: nr 
nr for bDAS 
AES: 
AD: 51.7 (11.5, nr) 
ALS: 33.2 (10.8, nr) 
Total: 42.4 (14.4, nr) 
43 
 




Residential status N Population 
(N of each subgroup, or % 
where N not possible to 
calculate) 









Apathy score  
Mean (SD, range)  
Total: 71.0 
(12.1, nr) 








ALS 68.0 (7.5, nr) 83.01%* ECAS cognitive 
score: 107.0 
(14.1,nr) 
nr for total score 
DAS-I subscales: 
Executive: 6.1 (4.8, nr) 
Emotional: 8.9 (4.2, nr) 
Initiation: 12.1 (5.5, nr) 
b-DAS  
Executive: 2.0 (2.0, nr) 
Emotional:  2.9 (1.9, nr) 
Initiation: 4.3 (2.6, nr) 
[81] DEX Japanese Reliability (test-retest); 
Hypothesis testing 




Alzheimer’s Disease 72.0 (7.7, nr) 37.70%* 20.8 (2.0, nr) nr 
[68] FrSBe-I English  ̂ Content validity (cognitive 
interview) 




N=10 People attending 
neuropsychological 
evaluation. 90% had 
memory complaints. 
Diagnoses nr. 
nr nr nr nr 
Structural validity; Internal 
consistency;  hypothesis 
testing (groups & 
divergent);   




N=494   Mixed sample: 
Dementia: AD (19.3%*), 
VaD (4.9%); Dementia not 
otherwise specified (4.1%); 













nr Original FrSBe-apathy:  
PD=33.29 (12.71); AD 




Revised FrSBe-apathy:  
PD=27.24 (10.13); AD 









Residential status N Population 
(N of each subgroup, or % 
where N not possible to 
calculate) 









Apathy score  
Mean (SD, range)  
Frontal stroke (7.2%). 
Head injury (2.1%). 
Other neurological 
disorder (<1%). 
[64] FrSBe-I English  ̂ Structural validity; Internal 
consistency 








No definitive diagnosis 
(NDD; N=28)  
Ctrl (N=47) 
79.12 (8.05; 
52 to 99)  
28.29%* nr 86.12 (24.39) 
[46,47]  GDS-30 English  ̂ Development (Item 
elicitation and pilot study) 
Item elicitation: n/a 
no participants 
Pilot: Community 
dwellers (N=20) and 
inpatients (N=51). 
N=71 Healthy older adults (Ctrl: 
N=20)  
Depressed older pts (Dep: 
N=51) 
nr. 
All over 55. 
nr nr nr 
[92] GDS-3A Dutch  ̂ Hypothesis testing 
(convergent validity) 
Community-dwelling Study 1  
N =427 
Older adults with mild 
cognitive deficits  
81.3 (4.6, nr) 
All at least 75 
and over 
39.8%* median (Q1 to 
Q3) 
26 (25 to 27) 
GDS-3a score:0 =52.8%; 
1=30.7%; 2=12.2%; 
3=4.4% 
AS: 11.3 (4.7) 
Study 2 
N=1118 
Older adults with 
depressive symptoms 
81.8 (4.9, nr) 
All at least 75 
and over 
38.9%* median (Q1 to 
Q3) 
28 (27 to 29) 
GDS-3a: 0 =64.2%; 1 
=25.6%; 2 =9.3%; 3 
=0.89% 
AS: 7.5 (4.6, nr) 
[69] GDS-6A English^ Internal consistency, 
Hypothesis testing 
(divergent & known 
groups) 
Community-dwelling N=140 Mixed sample: 
Dementia: AD (29.3%); 
VaD (29.3%); MD (13.6%) 
Cognitive disorder not 
specified or MCI (CNS-MCI, 
17.1%) 
Other (6.4%); None (2.1%) 
(2.2% nr) 
78.2 (7.23, nr) 
All at least 65 
or over 
35.0%* 24.86 (3.35, nr) GDS-6a: 1.66 (1.39, nr)   
45 
 




Residential status N Population 
(N of each subgroup, or % 
where N not possible to 
calculate) 









Apathy score  
Mean (SD, range)  
[82] GIP-a-s 
GIP-a-d 











Dementia: AD (82%); VaD 
(13%); Other dementia 
(3%);  
Other (affective disorder or 
other cognitive disorder, 
2%)  
median (Q1 
to Q3, range) 
80 (75.5 to 
84, 53 to 96) 




13.3 (10.4 to 16, 
3.5 to 20) 
Amsterdam 
Dementia 
Screening test 3: 




Screening test 5: 
1 (-1 to 3, -5 to 
8). 
N=56: 
GIP-a-s: 2.2 (2.3, 0 to 9) 




IMD Italian  ̂ Development (item 
elicitation) 
n/a no participants n/a n/a n/a n/a n/a n/a 
Hypothesis testing  
(divergent) 
Sample 1:  
Some Community-
dwelling and some 
institutionalised. 
Author unable to 
confirm proportion. 
N=236 nr, but at least some 
healthy older adults. 
Mild to moderate 
functional impairment 
(52.5%). Severe functional 
impairment (24.8%).  
74.2 (6.8, nr) 
  
40.6%*  19.4 (4.3, nr) 
  
nr  
Sample 2:  
nr.  
Author unable to 
confirm. 
N=203 Dementia  74.1 (5.56; 63 
to 83) 











People with TBI, their 
carers, and TBI 
rehabilitation specialists. 
nr nr nr nr 
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Residential status N Population 
(N of each subgroup, or % 
where N not possible to 
calculate) 









Apathy score  
Mean (SD, range)  
Development (item 
refinement) 
panel1: nr. panel 2 & 
3: n/a. 
N=14 Panel 1: carers for people 
with TBI (N=4) 
Panel 2: clinical 
psychologists (N=3) 
Panel 3: clinical 
neuropsychologists (N=7) 
nr nr nr nr 
[93] KBCI-a English  ̂ Hypothesis testing 
(divergent) 
Outpatients. No 
reply from author.  
N=97 Mixed sample: 
Ctrl (31%) 
MCI (18%) 
Probable AD (7%) 
Other (depression, CDNOS, 
PD, DLB, and possible AD) 
72.34 (9.05, 
nr) 
nr 26.89 (2.63, nr) nr 
[39] LARS French; English Development n/a – no participants 
involved. 
n/a n/a n/a n/a n/a n/a 











Dementia (Dem, N=101) 














Ctrl: 28.72 (1.42, 
nr) 
Dem: -0.16 (18.50, nr) 
Ctrl: -29.54 (5.44, nr) 
 
[70] LARS-I French  ̂ Internal consistency; 












PD without dementia 
(PDexclD, N=43)  












nr -16.18 (11.99, nr) 
[65] LARS - C Spanish Content validity; 
Structural validity; Internal 
consistency ; Reliability 
(interrater & test-retest); 














PD: 71.6 (8.1, 
nr) 
Ctrl: 69.4 (8.7, 
nr)  
PD: 60.0%*  
Ctrl: 55.7%* 
MEC:  
PD: 30.7 (3.8, nr)  
Ctrl: 33.3 (1.7, nr)  
PD: -14.5 (9.1, nr)  
Ctrl: -25.0 (5.5, nr) 
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Residential status N Population 
(N of each subgroup, or % 
where N not possible to 
calculate) 









Apathy score  
Mean (SD, range)  
Hypothesis testing 























Other dementia (N=6) 
Ctrl (N=49)  
Dem: 67.5 
(9.7, 38 to 85) 
Ctrl: 66.9 (8.4, 
51 to 82) 
Dem: 47.8%*  
Ctrl: 34.7%*   
Dem: 17.5 (6.8, 0 
to 29) 
Ctrl: 26.3 (2.3,19 
to 30) 
NPI-apathy total nr. 
Dem:  
Prevalence: 77.2%.  
Frequency: 2.52 (1.67; 0 
to 4) 
Severity: 1.75 (1.18; 0 to 
3) 
Ctrl:  
Prevalence =6.1%.  
Frequency =0.06 (0.24; 0 
to 1) 
Severity =0.06 (0.24; 0 to 
1) 
[51] NPI English  ̂ Development (item 
elicitation and Delphi 
study of 
comprehensiveness) 
Item elicitation: n/a 
no participants 
Delphi study: n/a 
professionals 
N=10 Geriatric psychiatrists, 
behavioural neurologists, 
and neuropsychologists 
n/a n/a n/a n/a 






Dementia (Dem) and 
healthy controls:  
AD (N=20) 
VaD (N=9) 
Other dementia (N=11) 
Ctrl (N=40) 
75.7 (56 to 
90) 
Dem: 55.00%*  
Control: 50.00%*   
Dem: 19.2 (0 to 
29)  
Control: 28.4 (25 
to 30)  
NPI-apathy total nr. 
Frequency: 2.83 (1.55; 0 
to 4) 
Severity: 1.35 (0.83; 0 to 
3) 










59 to 89) 
47% 19.26 (5.95; 1 to 
29) 
nr for total sample. 
Reported separately for 
two different severity 








Residential status N Population 
(N of each subgroup, or % 
where N not possible to 
calculate) 









Apathy score  
Mean (SD, range)  
Less severe dementia: 
4.69 (3.72, nr)  
More severe dementia: 
7.45 (4.45, nr)  
[73] NPI Farsi Internal consistency; 
Reliability (interrater & 
test-retest); Hypothesis 
testing (convergent, 
divergent & known 
groups) 
51% living with 




















(8.3, 60 to 90) 
Ctrl: 74.3yrs 
(8.5) 
Dem: 47%  
Ctrl: 51%  




Dem: 11.3 (7.5, 
nr)  
Ctrl: 29.4 (1.0, nr) 
NPI-apathy total nr. 
Prevalence: 74% 
Frequency 2.5 (1.7, nr) 
Severity 1.6 (1.1, nr) 


















35 to 85)  
49.21%*  nr NPI-apathy total nr. 
 Prevalence: 56%  






N=29 Dementia 71.05 (5; 60 
to 84) 
60% 12.4 (6.0; 0 to 24) 5.8 (4.4, nr)   
[86] NPI Chinese reliability Community dwelling N=91 Dementia and healthy 
controls. 
Dementia (Dem, N=62*): 




(7.0; 54 to 
88). 
Ctrl: 74.9 (4.7; 
68 to 86) 
Dem: 22.58%* 
Ctrl: 72.41%* 
Dem: 12.7 (5.9; 0 
to 25.) 
Ctrl: 27.5 (2.2; 23 
to 30.) 
nr 
[84] NPI Brazilian 
Portuguese 






N=36 Alzheimer’s Disease  78.78 (7.48) 22%* 7.06 (6.92) NPI-apathy total nr. 
Severity: 5.31 (4.91) 
Frequency: 1 =33%, 2 
=3%, 3 =64%. 
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Residential status N Population 
(N of each subgroup, or % 
where N not possible to 
calculate) 









Apathy score  
Mean (SD, range)  
[96] NPI Dutch divergent validity 83.33% community-
dwelling 
N=24 Mixed sample:  
Dementia: AD (N=19), FtD 
(N=1), MD (N=1) 
Stroke (N=2) 
Amnestic disorder (N=1) 
74.3 (10.4, nr) 33.33%* 21.5 (4.6; 12 to 
29)." 
nr 
[66] NPI-A English  ̂ Structural Validity; 
Internal consistency.  
Outpatients. Author 




N=124 Dementia:  
AD (N=62) 
VaD (N=43) 
MD of AD+VaD  (N=19) 
79.8 (6.1; 61 
to 91) 
21.77%* 22.6 (3.5; 13 to 
29) 
8.89 (8.5, nr) 






Content validity (further 
item elicitation and Delphi 
study)  
Item elicitation: n/a 
no participants 




Experts in dementia 
research 






N=128  Alzheimer’s Disease 75.7 (9.0; 54 
to 94) 
nr 17.6 (7.0; 0 to 
28). 
NPI-C-apathy total nr. 
AES (N=113): 33.1 (11.3; 
0 to 51) 
[88] NPI-C Portuguese Reliability (interrater); 
Hypothesis Testing 
(convergent) 
Author confirmed all 
community via 
correspondence 
N=156  Dementia 76.7 (nr, nr) 26.28%* 17.2 (nr, nr) NPI-C-apathy total nr. 
AI: 5.9 (nr, nr) 
[52] UPDRS English Development (item 
elicitation and review of 
comprehensibility) 
n/a no participants 
involved 
n/a n/a n/a n/a n/a n/a 
[100] UPDRS Spanish  ̂ Hypothesis Testing 
(convergent) 










Parkinson's Disease  65.9 (9.8, nr) 57% 24.4 (5.4, nr) nr 
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Residential status N Population 
(N of each subgroup, or % 
where N not possible to 
calculate) 









Apathy score  
Mean (SD, range)  
[99] UPDRS Norwegian  ̂ Hypothesis Testing 
(convergent) 
nr. Participants were 
assessed in 
outpatient clinics, at 










Parkinson’ Disease  
(41.4% with cognitive 
impairment) 
74.2 (8.8, nr) 44.8% 23.0 (7.2, nr) UPDRS-apathy item nr. 
17% had apathy 
according to diagnostic 
criteria. 







N=301 Parkinson’s Disease 67.8 (10.6; 30 
to 90) 
63% nr 1.14 (1.1; 0 to 4)  
AS =13.7 (6.9) range =0 
to 31. 





English Development (Item 
elicitation [including 
adaptation of items from 
UPDRS to create mds-
UPDRS], Pilot study) 
nr nr Item elicitation: nr.  
Pilot study:  
Part 1: Patients (PD, N=80), 
carers (N=nr) and 
professionals (N=nr) 
Part 2: Patients (N=32) and 
professionals (N=14) 
nr nr nr nr 
[97] mds-
UPDRS 






N=584 Parkinson’s Disease 
PD with neurocognitive 
disorder (N=310) 
PD with depression 
(N=217) 
Apathy status: No apathy 




67 (61 to 73.  
Apathy: 68 
(61 to 75) 








28, (27 to 29) 
Apathy: 27 (24 to 
28)  
median (Q1 to Q3) 
LARS:  
No apathy: -26 (-30 to -
21) 
Apathy: -15 (-22 to 5) 
Note: Where the study had used secondary data, the primary data sources were sought to gain the necessary information where it was not available in the article in question. 45 
^ Assumed based on location of study and/ or nationality of participants. 46 
*Calculated by authors 47 
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Abbreviations: AD-RD, Alzheimer's Disease and Related Dementias Mood Scale; ACE, Addenbrooke’s Cognitive Examination; AD, Alzheimer’s Disease; AES-12PD, Apathy Evaluation Scale 12-48 
item Parkinson’s Disease; AES-C, Apathy Evaluation Scale Clinician; AES-I, Apathy Evaluation Scale Informant; AES-S, Apathy Evaluation Scale Self; AI, Apathy Inventory; AI-C, Apathy Inventory 49 
Clinician; AI-I, Apathy Inventory Informant; ALS, Amyotrophic Lateral Sclerosis; AMI, Apathy Motivation Index; AS-S, Apathy Scale Self; AS-I, Apathy Scale Informant; bDAS, brief Dementia 50 
Apathy Scale; BMDS, Behavioural and Mood Disturbance Scale; BSSD, Behavioral Syndromes Scale for Dementia; CD, Current Depression; CDNOS, Cognitive Disorder Not Otherwise 51 
Specified; Ctrl, Healthy Controls; DAIR, Dementia Apathy Interview Rating; DAS, Dementia Apathy Scale; DAS-I, Dementia Apathy Scale Informant; DAS-S, Dementia Apathy Scale Self; Dem, 52 
Dementia; Dep, Depression; DEX, Dysexecutive Questionnaire; DLB, Dementia with Lewy Bodies; FrSBe-I, Frontal Systems Behavior Scale Informant; FtD, Frontotemporal Dementia; GDS, 53 
Geriatric Depression Scale; GIP, Behavioral Rating Scale for Psychogeriatric Inpatients ; IMD, Index of Mental Decline; KBCI, Key Behaviors Change Inventory; LARS, Lille Apathy Rating Scale; 54 
LARS-C, Lille Apathy Rating Scale Clinician; LARS-I, Lille Apathy Rating Scale Informant; LHS, Left Hemisphere Stroke; MCI, Mild Cognitive Impairment; MCS, Mild Cognitive Symptoms; MD, 55 
Mixed Dementia; mds-UPDRS, Movement disorder Society Unified Parkinson’s Disease Rating Scale; NPI, Neuropsychiatric Inventory; NPI-A, Neuropsychiatric Inventory Alternative; NPI-C, 56 
Neuropsychiatric Inventory Clinician; nr, not reported; PD, Parkinson’s Disease; PDa&d, Parkinson’s Disease with apathy and depression; PDa, Parkinson’s Disease with apathy; PDD, 57 
Parkinson’s Disease Dementia; PDd, Parkinson’s Disease with depression; PDDd, Parkinson’s Disease with dementia and depression; PDexclD, Parkinson’s Disease without dementia; 58 
PDexclDd, Parkinson’s Disease without dementia or depression; PS, Parkinsonian Symptoms; RD, Remitted Depression; RHS, Right Hemisphere Stroke; SCD, Subjective Cognitive Decline; 59 
UPDRS, Unified Parkinson’s Disease Rating Scale; VaD, Vascular Dementia. 60 
 61 
  62 
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Relevance Comprehensiveness Comprehensibility 
Methodological 
quality 
Result (quality rating) Methodological 
quality 
Result (quality rating) Methodological 
quality 
Result (quality rating) 




and expert review 





Construct of apathy is not clear. Items were 
all based on their mention by at least two 
carers (informal or formal) in qualitative 
interviews about how people with 
dementia express their mood. No 
justification was provided for the response 
options or recall period. (1?)  
Doubtful Patients or carers were not 
asked specifically about the 
measure. Expert review lead 
to reduction of items to avoid 
repetition. However, it was 
unclear what professionals 
were asked. (1?). 
Doubtful Patients or carers were not asked 
specifically about the measure. 
Expert review lead to modified 
instructions. However, it was 
unclear what professionals were 
asked (1?). 
[33] AES Y Development 
study and pilot 
study.  
Inadequate Construct of apathy is clear. Items were 
developed from the literature, 
professionals, and authors’ observations 
and opinions of people with apathy, but 
participants not involved in eliciting items 
and observations not reported on. (1?). 
  Doubtful Unclear what participants were 
asked. 14 items were removed 
from the preliminary item pool due 
to poor comprehensibility. (1?). 
[34] AI Y Development 
study. 
Inadequate Construct of apathy is clear. Items were 
developed from the literature and 
diagnostic criteria, but participants not 
involved in eliciting items. (1?). 
    
[35] AMI N Development 
study. 
Inadequate Construct of apathy is clear. Items were 
developed from the relevant items of the 
LARS and by professionals. Participants 
were not involved in eliciting items. (1?).  
    
[36] AS Y Development 
study (Adaptation 
of AES to make 
AS.) 
 
Inadequate Construct of apathy is clear. Participants 
not involved in eliciting items. Most 
relevant items of AES were selected by 2 
professionals (S. Starkstein personal, 
communication, October 01, 2018). (1?). 
Doubtful Pilot study conducted with 
participants with neurological 
disorders, but not published, 
so unable to rate. New items 
were included by 2 
professionals (S. Starkstein 
personal, communication, 
October 01, 2018). (1?). 
Inadequate Pilot study conducted with 
participants with neurological 
disorders, but not published, so 
unable to rate. Some items were 
modified by 2 professionals (S. 
Starkstein personal, 
communication, October 01, 2018). 
(1?). 
[90] AS-I Y Content validity 
study. 
    Doubtful Unclear what participants were 
asked. Participants showed good 
understanding and no 










Relevance Comprehensiveness Comprehensibility 
Methodological 
quality 
Result (quality rating) Methodological 
quality 
Result (quality rating) Methodological 
quality 
Result (quality rating) 
[42] BMDS Y Development 
study. 
Inadequate Constructs of behaviour and mood, and 
apathy were not clear. Items were 
developed from the literature and author 
opinion, but participants not involved in 
eliciting items. (1?). 
    
[43] BSSD Y Development 
study and pilot 
study. 
Inadequate Items were developed from professionals 
and previous measures, but participants 
not involved in eliciting items.  (1?). 
Doubtful Multiple pilot studies 
conducted to refine scale, but 
methods and results not 
reported. (1?). 
Doubtful Multiple pilot studies conducted to 
refine scale, but methods and 
results not reported. (1?). 
[37] DAIR Y Development 
study and pilot 
study. 
Doubtful Construct of apathy is clear. Items refer to 
apathy, and were developed with 
participation from people with dementia 
and carers. No justification was provided 
for the response options or recall period. 
(1+/-).  
Doubtful Unclear what participants 
were asked. (1?). 
Doubtful Unclear what participants were 
asked. (1?). 
[38]  DAS Y Development 
study. 
Inadequate Items were developed from existing scales 
and experts, but participants not involved 
in eliciting items. (1?). 
    
[68] FrSBe-
11a 
Y Content validity: 
cognitive 
interviewing study 
    Doubtful 27% items had no discrepancies, 
with 82% of items having 
acceptable discrepancy*. However, 
participants do not appear to have 
been asked about the 
comprehensibility of instructions or 
response options. (1?) 
[68] FrSBe-
14a 
Y Content validity: 
cognitive 
interviewing study 
    Doubtful 21% items had no discrepancies, 
with 
86% of items having acceptable 
discrepancy*. However, 
participants do not appear to have 
been asked about the 
comprehensibility of instructions or 
response options. (1?) 
[46,47] GDS N Development and 
pilot study (as a 
Inadequate Items were developed from professionals, 
but participants not involved in eliciting 
items. (1?). 
  Doubtful Reported that patients accepted 










Relevance Comprehensiveness Comprehensibility 
Methodological 
quality 
Result (quality rating) Methodological 
quality 
Result (quality rating) Methodological 
quality 
Result (quality rating) 
measure of 
depression) 
which this was ascertained were 
unclear. (1?) 
[49] IMD Y Development Inadequate Items were developed from existing 
measures and professionals, but 
participants not involved in eliciting items. 
(1?). 
    
[50,104] KBCI N Development and 
pilot 
Doubtful Construct of apathy clear. Items were 
developed from the literature and 
interviews with patients, carers and 
professionals. Methods not clear. No 
justification for response options and recall 
period not clear. Patients and carers were 
later asked to rate the importance of items, 
and the majority were rated very or 
extremely important, but exact ratings not 
reported. (1+/-). 
Doubtful Patients and carers did not 
suggest any additional items. 
However, items were later 
removed after another phase 
in the development, so 
comprehensiveness may 
have changed. Method not 
clear. (1?) 
Doubtful. Patients and carers were asked 
about comprehensibility and no 
changes were suggested. 
Professionals were asked about 
comprehensibility and 15 items 
were re-worded. Methods and 
focus not clear (e.g. whether they 
were asked about each item, 
response options and recall period) 
(2?) 
[39]  LARS N Development Inadequate Items were developed from Marin’s 
concept of apathy and authors’ clinical 
experience, but no systematic process and 
participants not involved in eliciting items. 
(1?). 
    
[65] LARS Y Pilot study Doubtful Participants asked about relevance, but 
results not reported. Methods and focus 
not clear (e.g. whether they were asked 
about each item, response options and 
recall period) (1?) 
  Doubtful Participants asked about 
comprehensibility and format. 
Methods and focus not clear (e.g. 
whether they were asked about 
comprehensibility of instructions 




NPI N Development and 
Delphi study 
Inadequate Items developed from the literature, but 
participants not involved in eliciting items. 
(1?).  
Doubtful Delphi panel of 10 
professionals. Assessed 
“whether the essential 
elements of the behavior 
were captured” in each 
domain by rating screening 
and sub questions from 1 
(well assessed) to 4 (poorly 











Relevance Comprehensiveness Comprehensibility 
Methodological 
quality 
Result (quality rating) Methodological 
quality 
Result (quality rating) Methodological 
quality 
Result (quality rating) 
questions mean score = 1.3; 
sub-questions mean score = 
1.4. No assessment of 
comprehensiveness by 
participants. (1?) 
[87] NPI-C Y Content validity 
(adaptation) 
Doubtful New items added from symptoms listed by 
alternative measures. Items were selected 
that were consistent with diagnostic 
criteria 2009. Participants not involved in 
eliciting new items. (1?) 
Doubtful Delphi panel of 8 
professionals. Unclear what 
was asked. (1?) 
Doubtful Delphi panel of 8 professionals. 
Unclear what was asked. (1?) 
[52] UPDRS N Development 
study 
Inadequate Expert group elicited items from existing 
measures, but participants not involved in 
eliciting items. (1?). 
  Inadequate Authors reviewed 
comprehensiveness of preliminary 
items. Changes were made and 
final version does not appear to 












Expert group elicited items from literature, 
existing measures, clinical experience and 
participant survey, though methods not 
described in sufficient detail. Justification 
provided for response options but not 
recall period. (1?). 
  Doubtful Comprehensiveness of preliminary 
items was reviewed by participants 
and professionals in a qualitative, 
then quantitative study. Items, 
instructions and response options 
were assessed. Unsure if recall 
period discussed. Changes were 
made in the first round and then 
again in the second round. (1?) 
Note: Studies only listed if they assessed content validity in some way or were a study describing the development of a measure. Some studies have multiple citations as multiple articles or 64 
similar (e.g. PhD thesis) were published on the same study. Blank cells indicate this measurement property was not investigated by the study. 65 
Quality of measurement property: Number of studies in parenthesis followed by rating: +, Sufficient; +/-, Inconsistent; -, Insufficient; ?, Indeterminate.  66 
* Acceptable discrepancy was defined by the authors of the study as less than 30% of participants interpreting the items meaning in the way it was intended [68]. 67 
Abbreviations: AD-RD, Alzheimer's Disease and Related Dementias Mood Scale; AES Apathy Evaluation Scale; AMI, Apathy Motivation Index; AI, Apathy Inventory; AS, Apathy Scale; AS-I, 68 
Apathy Scale Informant; BMDS, Behavioural and Mood Disturbance Scale; BSSD, Behavioral Syndromes Scale for Dementia; DAIR, Dementia Apathy Interview Rating; DAS, Dimensional 69 
Apathy Scale; FrSBe-11a, Frontal Systems Behavior Scale 11 item apathy subscale; FrSBe-14a, Frontal Systems Behavior Scale 14 item apathy subscale; GDS, Geriatric Depression Scale; IMD, 70 
Index of Mental Decline; KBCI, Key Behaviors Change Inventory; LARS, Lille Apathy Rating Scale; mds-UPDRS, Movement Disorder Society Unified Parkinson’s Disease Rating Scale; NPI, 71 
Neuropsychiatric Inventory; NPI-C, Neuropsychiatric Inventory Clinician; UPDRS, Unified Parkinson’s Disease Rating Scale. 72 









Table S.4. Reviewer rating of content validity 77 
Measure Relevance  Comprehensiveness 
(quality rating) 
Comprehensibility (quality rating) Overall validity 
 Older adults (quality rating) Dementia & MCI (quality rating) Older adults  Dementia & MCI  
AD-RD  
 
Unable to obtain the full list of items and 
instructions. 
     
AES 94% relevant to apathy. 100% relevant 
to older adults. 94% relevant to research 
context. Response options appropriate. 
Suggested recall period too long, but 
personalised recall period also possible. 
(1+). 
AES-I & AES-S: 94% relevant to apathy. 
100% relevant to people with dementia. 
94% relevant to research context. 
Response options appropriate. Suggested 
recall period too long, but personalised 
recall period also possible. (1+).  
AES-C: 94% relevant to apathy. 78% 
relevant to people with dementia, as some 
items based on where some items are 
rated based on patient free-recall. 94% 
relevant to research context. Response 
options appropriate. Suggested recall 
period too long, but personalised recall 
period also possible. (1+/- ). 
3 domains of apathy 
included. (1+). 
AES-I & AES-S: 94% appropriately worded. 72% 
match response options. (1+/-). 
AES-C: has additional guidance around this so 
AES-C response options deemed appropriate. 
(1+). 
Sufficient 
(AES-I & AES-S: 2+, 1+/-
;  
AES-C: 3+) 
Sufficient (2+, 1+/-) 
AI 100% items relevant to apathy, older 
adults and the research context. 
Response options appropriate for AI-C 
and AI-I, but not for AI-S. Recall period 
referencing onset of disease not 
appropriate for older adults, but 
personalised recall period possible.  
(Using the given recall period: 1+/-. 
Using the personalised recall period: 1+.) 
100% items relevant to apathy, people 
with dementia and the research context. 
Response options appropriate for AI-C and 
AI-I, but not for AI-S. Recall period of since 
onset of disease too long for people with 
dementia, but personalised recall period 
possible.  
(Using the given recall period: 1+/-. Using 
the personalised recall period: 1+.) 
3 domains of apathy 
included. (1+). 
0% of items appropriately worded. (1-) Inconsistent (Given 
recall period: 1+, 1-, 
1+/-; Personalised 
recall period: 2+, 1-) 
Inconsistent (Given 
recall period: 1+, 1-, 
1+/-; Personalised 
recall period: 2+, 1-) 
AMI 78% relevant to apathy. 100% relevant 
to older adults. 100% relevant to 
research context. Response options and 
recall period appropriate. (1+/-). 
78% relevant to apathy and to older adults. 
100% relevant to research context. 
Response options and recall period 
appropriate. (1+/-). 
3 domains of apathy 
included. (1+). 
100% of items appropriately worded. 100% 
match response options. (1+). 
Sufficient (2+, 1+/-) Sufficient (2+, 1+/-) 
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Measure Relevance  Comprehensiveness 
(quality rating) 
Comprehensibility (quality rating) Overall validity 
 Older adults (quality rating) Dementia & MCI (quality rating) Older adults  Dementia & MCI  
AS 93% relevant to apathy. 93% relevant to 
older adults.100% relevant to research 
context. Response options appropriate. 
Recall period too long. (1+). 
93% relevant to apathy. 100% relevant to 
people with dementia and the research 
context. Response options appropriate. 
Recall period too long. (1+) 
3 domains of apathy 
included. (1+). 
93% of items appropriately worded. 57% match 
response options (1+/-) 
Sufficient (2+, 1+/-) Sufficient (2+, 1+/-) 
BMDS 55% relevant to apathy. 100% relevant 
to older adults and the research context. 
Response options appropriate. Recall 
period uncertain. (1+/-). 
55% relevant to apathy. 100% relevant to 
people with dementia and the research 
context. Response options appropriate. 
Recall period uncertain. (1+/-). 
Emotional dimension 
missing. (1-). 
100% of items appropriately worded, but 
combination with response options produces 
double negatives. (1+/-). 
Inconsistent (1-, 2+/-) Inconsistent (1-, 
2+/-) 
BSSD 71% relevant to apathy. 100% relevant 
to older adults and research context. 
14% response options appropriate. 
Recall period appropriate. (1+/-) 
71% relevant to apathy. 100% relevant to 
people with dementia and research 
context. 14% response options 
appropriate. Recall period appropriate. 
(1+/-) 
3 domains of apathy 
included. (1+). 
86% of items (questions directed at informants) 
appropriately worded. 100% match response 
options. (1+). 
Sufficient (2+, 1+/-) Sufficient (2+, 1+/-) 
DAIR 94% items relevant to apathy. 0% 
relevant for healthy older adults due to 
mandatory follow-up question relating 
to “illness”. Response options 
appropriate. Recall period too long. 
(1+/-). 
94% items relevant to apathy. 100% 
relevant for people with dementia. 
Response options appropriate. Recall 
period too long. (1+). 
3 domains of apathy 
included. (1+). 
100% items appropriately worded. 81% match 
the response options. (1+/-). 
Inconsistent (1+, 2+/-). Sufficient (2+, 1+/-). 
DAS DAS: 79% items relevant to apathy.  
bDAS: 67% items relevant to apathy 
Both versions: 100% relevant to older 
adults. Response options appropriate. 
Recall period too long. (1+/-). 
DAS: 79% items relevant to apathy.  
bDAS: 67% items relevant to apathy 
Both versions: 100% relevant to people 
with dementia. Response options 
appropriate. Recall period too long. (1+/-). 
3 domains of apathy 
included. (1+). 
100% of items appropriately worded. 100% 
match response options. (1+). 
Sufficient (2+, 1+/-). Sufficient (2+, 1+/-). 
DEX 
 
63% items relevant to apathy. 100% 
relevant to older adults and research 
context. Complete response options not 
available. Recall period appropriate. 
(1+/-).* 
63% items relevant to apathy. 100% 
relevant to people with dementia and 
research context. Complete response 
options not available. Recall period 
appropriate. (1+/-).* 
3 domains of apathy 
included. (1+).* 
Full wording not available, but 75% of items 
appear appropriately worded. Complete 
response options not known. (1?).  






Measure Relevance  Comprehensiveness 
(quality rating) 
Comprehensibility (quality rating) Overall validity 
 Older adults (quality rating) Dementia & MCI (quality rating) Older adults  Dementia & MCI  
FrSBe  
 
FrSBe-6a: 83% relevant to apathy. 100% 
relevant to older adults.  
FrSBe-11a: 82% relevant to apathy. 91% 
relevant to older adults. 
FrSBe-14a: 86% relevant to apathy. 93% 
relevant to older adults. 
And all versions: 100% relevant to 
research context. Response options not 
available. Recall period not appropriate 
for older adults. (1+/-).* 
FrSBe-6a: 83% relevant to apathy. 100% 
relevant to older adults 
FrSBe-11a: 82% relevant to apathy. 91% 
relevant to people with mild dementia.  
FrSBe-14a: 86% relevant to apathy. 93% 
relevant to mild dementia.  
And all versions: 100% relevant to research 
context. Response options not available. 
Recall period not appropriate for people 
with dementia. (1+/-).* 
All versions: 3 domains of 
apathy included. (1+).* 
6a: Full wording not available, but items 
suggests that 67% appropriately worded. 
Response options not available. (1?). 
11a: Full wording not available, but items 
suggests that 91% appropriately worded. 
Response options not available. (1?). 
14a: Full wording not available, but items 
suggests that 86% appropriately worded. 
Response options not available. (1?). 




GDS-3a 67% of items are relevant to apathy. All 
items relevant to older adults and the 
research context. Dichotomous 
response options not appropriate. Recall 
period appropriate. (1+/-). 
67% of items are relevant to apathy. All 
items relevant to people with dementia 
and the research context. Dichotomous 
response options not appropriate. Recall 
period appropriate. (1+/-).  
Emotional dimension of 
apathy is missing (1-). 
100% appropriately worded and match 
response options. (1+). 
Inconsistent (1+, 1-, 
1+/-) 
Inconsistent (1+, 1-, 
1+/-) 
GDS-6a 50% of items are relevant to apathy. All 
items relevant to older adults and the 
research context. Dichotomous 
response options not appropriate. Recall 
period appropriate. (1+/-). 
50% of items are relevant to apathy. All 
items relevant to older adults and the 
research context. Dichotomous response 
options not appropriate. Recall period 
appropriate. (1+/-). 
3 domains of apathy 
included. (1+). 
100% appropriately worded and match 
response options. (1+). 
Sufficient (2+, 1+/-) Sufficient (2+, 1+/-) 
GIP-9a  44% of items relevant to apathy. 89% 
relevant to older adults in the 
community. 100% relevant to research 
context. Recall period appropriate. 
Response options not available. (1+/-).* 
44% of items relevant to apathy. 89% of 
items relevant to people with dementia in 
the community. 100% relevant to research 
context. . Recall period appropriate. 
Response options not available. (1+/-).* 
Emotional dimension of 
apathy is missing. (1-).* 
Full wording and official English translation of 
items not available, but authors translation 
suggest 89% appropriately worded. Response 
options not available. (1?).* 




IMD 100% of items relevant to apathy, older 
adults and the research context. 
Response options and recall period not 
available. (1?). 
100% of items relevant to apathy, people 
with dementia and the research context. 
Response options and recall period not 
available. (1?). 
3 domains of apathy 
included. (1+). 
Full wording not available, but items suggest 
33% appropriately worded. Response options 
not available. (1?). 
Indeterminate (1+, 2?) Indeterminate (1+, 
2?) 
KBCI-10a  90% of items relevant to apathy. 80% of 
items relevant to older adults. All items 
relevant to research context. Response 
90% of items relevant to apathy. 80% of 
items relevant to people with dementia. 
All items relevant to research context. 
3 domains of apathy 
included. (1+). 
80% of items appropriately worded. 100% 
match response options. (1+/-). 




Measure Relevance  Comprehensiveness 
(quality rating) 
Comprehensibility (quality rating) Overall validity 
 Older adults (quality rating) Dementia & MCI (quality rating) Older adults  Dementia & MCI  
options appropriate. Recall period not 
available. (1+/-). 
Response options appropriate. Recall 
period not available. (1+/-). 
LARS 94% of items relevant to apathy. 100% 
relevant to older adults. Response 
options appropriate. Recall period too 
long. (1+). 
94% of items relevant to apathy. 94% 
relevant to people with dementia. 
Response options appropriate. Recall 
period too long. (1+). 
3 domains of apathy 
included. (1+). 
87% appropriately worded. 100% match 
response options. (1+). 
Sufficient (3+) Sufficient (3+) 
NPI 
(original)  
100% of items relevant to apathy, older 
adults and the research context. 
Response options appropriate. 
Suggested recall period too long, but 
personalised recall period also possible. 
(1+). 
100% of items relevant to apathy, people 
with dementia and the research context. 
Response options appropriate. Suggested 
recall period too long, but personalised 
recall period also possible. (1+). 
Emotional dimension of 
apathy is missing from 
the screening questions. 
No dimensions are rated 
separately. (1-). 
Assessments of frequency and severity are 
based on multiple symptoms, so could be 
considered a double barrelled question and 
therefore not appropriately worded. However 
carers are advised to rate the worst one. 100% 
match the response options. (1+). 
Inconsistent (2+, 1-) Inconsistent (2+, 1-) 
NPI-A  
 
Unable to obtain full instructions and 
guidance.  
     
NPI-C 100% of items relevant to apathy, older 
adults and the research context. 
Response options appropriate. Recall 
period too long. (1+). 
100% of items relevant to apathy, people 
with dementia and the research context. 
Response options appropriate. Recall 
period too long. (1+). 
3 domains of apathy 
included. (1+). 
Assessments of frequency and severity are 
based on multiple symptoms, so could be 
considered a double barrelled question and 
therefore not appropriately worded. However 
carers are advised to rate the worst one. 100% 
match the response options. (1+). 
Sufficient (3+) Sufficient (3+) 
UPDRS  
 
100% relevant to apathy, older adults 
and research context. (Note: only 1 
item). Response options appropriate. 
Recall period not clear. (1+). 
100% relevant to apathy, people with 
dementia and research context. (Note: 
only 1 item). Response options 
appropriate. Recall period not clear. (1+). 
Emotional domain of 
apathy missing. Cognitive 
and Behavioural 
elements included but 
not rated separately. (1-). 
Item wording is not given, or could not be 
obtained; only the heading is provided, so it is 
unclear if it matches the response options. (1?). 




100% relevant to apathy, older adults 
and the research context. (Note: only 1 
item). Response options and recall 
period appropriate. (1+). 
100% relevant to apathy, people with 
dementia and the research context. (Note: 
only 1 item). Response options and recall 
period appropriate. (1+). 
Emotional domain of 
apathy missing. Cognitive 
and Behavioural 
elements included but 
not rated separately. (1-). 
100% appropriate worded and match response 
options. (1+). 
Inconsistent (2+, 1-) Inconsistent (2+, 1-) 
*based on list of apathy items presented by another publication (DEX [81]; FrsBE [64,68]; GIP [107]) 78 
Quality of measurement property: Number of studies in parenthesis followed by rating: +, Sufficient; +/-, Inconsistent; -, Insufficient; ?, Indeterminate.  79 
61 
 
Abbreviations: AD-RD, Alzheimer's Disease and Related Dementias Mood Scale; AES Apathy Evaluation Scale; AES-C, Apathy Evaluation Scale Clinician; AES-I, Apathy Evaluation Scale 80 
Informant; AES-S, Apathy Evaluation Scale Self; AI, Apathy Inventory; AI-C, Apathy Inventory Clinician; AI-I, Apathy Inventory Informant; AI-S, Apathy Inventory Self; AMI, Apathy Motivation 81 
Index; AS, Apathy Scale; b-DAS, brief-Dimensional Apathy Scale; BMDS, Behavioural and Mood Disturbance Scale; BSSD, Behavioral Syndromes Scale for Dementia; DAIR, Dementia Apathy 82 
Interview Rating; DAS, Dimensional Apathy Scale; DEX, Dysexecutive Questionnaire; FrSBe, Frontal Systems Behavior Scale; FrSBe-6a, Frontal Systems Behavior Scale 6-item apathy subscale; 83 
FrSBe-11a, Frontal Systems Behavior Scale 11-item apathy subscale; FrSBe-14a, Frontal Systems Behavior Scale 14-item apathy subscale; GDS-3a, Geriatric Depression Scale 3 item apathy 84 
subscale; GDS-6a, Geriatric Depression Scale 6 item apathy subscale; GIP-9a, Behavioral Rating Scale for Psychogeriatric Inpatients 9 item apathy subscale; IMD, Index of Mental Decline; 85 
KBCI-10a, Key Behaviors Change Inventory 10 item apathy subscale; LARS, Lille Apathy Rating Scale; MDS-UPDRS, Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s 86 
Disease Rating Scale; NPI, Neuropsychiatric Inventory; NPI-A, Neuropsychiatric Inventory Alternative; NPI-C, Neuropsychiatric Inventory Clinician; UPDRS, Unified Parkinson’s Disease Rating 87 
Scale  88 
 89 




Table S.5. Risk of bias and results of studies of remaining measurement properties 92 
Reference 
 










  Methodological 
quality 



















Result (quality rating) 
[40] AD-RD     1 Doubtful. r=.72 (1+).     
[78] AES-
12PD 
  3 Very good. α=.90 to .92 
(3+) 
    3 Adequate. 1 Very 
Good. 
3 met hypothesis (3+). 1 
did not meet hypothesis 
(1-). 
[53] AES-C 1 Doubtful. 3 factors (57.06%): 
Apathy (40.02%); 
Novelty Seeking 
(9.35%); Insight & social 
(7.68%). [1+] 
1 Very good. α=.90. (1+). 2 Doubtful. r=.88 to .86 
(2+). 
  2 Inadequate. 2 
Very Good. 
4 met hypothesis (4+). 
[54] AES-C 1 Doubtful. 2 factors (51.1%): 
Apathy (42.4%); 
Interest (8.7%). [1+] 
      1 Inadequate. 1 
Doubtful. 2 
Adequate. 
2 met hypothesis (2+). 2 
did not meet hypothesis 
(2-). 
[55] AES-C 1 Inadequate. 3 factors (84.17 )̂: 
Interest & Motivation 
(39.72% )̂; Task 
Completion (29.67%^); 
Insight (14.78% )̂. [1-] 
1 Very good. α=.93. (1+).     1 Inadequate. 1 
Doubtful. 1 Very 
Good. 
3 met hypothesis (3+).  
[33] AES-C 1 Inadequate. 3 factors: Apathy (32-
53%); Novelty Seeking 
(5-10%); Insight & 
dependency (7-8%). 
[1?] 
1 Very good. α=.90. (1+). 1 Doubtful. 1 
Adequate. 
r=.88 (1+). 
ICC= .94 (+). 
  3 Inadequate. 1 
Doubtful. 1 
Adequate. 4 Very 
Good. 
5 met hypothesis (5+). 1 
did not meet hypothesis 
(1-). 3 insufficient 
information (3?). 
[54] AES-I 1 Doubtful.  2 factors (54.4%): 
Interest (45.1%); 
Apathy (9.3%). [1+] 
      1 Inadequate. 1 
Doubtful. 2 
Adequate. 
2 met hypothesis (2+). 2 
did not meet hypothesis 
(2-). 
[55] AES-I   1 Very good. α=.89. (1+).     1 Inadequate. 1 
Doubtful.  1 Very 
Good. 















  Methodological 
quality 



















Result (quality rating) 
[33] AES-I 1 Inadequate. 3 factors: Apathy (32-
53%); Novelty Seeking 
(5-10%); Insight & 
dependency (7-8%). 
[1?] 
1 Very good. α=.94. (1+). 1 Doubtful. r=.94 (1+).   3 Inadequate. 1 
Doubtful. 1 
Adequate. 4 Very 
Good. 
4 met hypothesis (4+). 2 
did not meet hypothesis 
(2-). 3 insufficient 
information (3?). 
[56] AES-I 1 Doubtful. 1 
Adequate. 
2 factors (62.56%^): 
Factor 1 (56.2%); Factor 
2 (6.36%). [1+]. 
1 factor (62.8%). [1+]. 
1 Very good. α=.95. (1+).   n/a SEM=2.9. (1?). 2 Very Good. 2 met hypothesis (2+). 
[89] AES-I         1 Adequate. 2 Very 
good. 
1 met hypothesis (1+). 2 
did not meet hypothesis 
(2-). 
[71] AES-I   1 Very good. α=.88. (1+).       
[71] AES-I-16   1 Very good. α=.90. (1+).     1 Adequate. 1 Very 
Good 
1 met hypothesis (1+).  
1 did not meet 
hypothesis (1-). 
[55] AES-S   1 Very good. α=.90. (1+).      1 Inadequate. 1 
Doubtful.  1 Very 
Good. 
1 met hypothesis (1+). 1 
did not meet hypothesis 
(1-). 1 insufficient 
information (1?) 
[54] AES-S 1 Doubtful. 2 factors (43.3%^): 
Apathy (36.4%); Other 
(6.9%) [1+] 
      1 Inadequate. 1 
Doubtful. 2 
Adequate. 
2 met hypothesis (2+). 2 
did not meet hypothesis 
(2-). 
[33] AES-S 1 Inadequate. 3 factors: Apathy (32-
53%); Novelty Seeking 
(5-10%); Insight & 
dependency (7-8%). 
[1?] 
1 Very good. α=.86. (1+). 1 Doubtful. r=.76 (1+).    3 Inadequate. 1 
Doubtful. 1 
Adequate. 4 Very 
Good. 
5 met hypothesis (5+). 1 
did not meet hypothesis 
(1-). 3 insufficient 
information (3?) 
[56] AES-S 1 Doubtful. 1 
Adequate. 
2 factors (61.69%^): 
Factor 1 (55.37%); 
Factor 2 (6.32%). [1+] 
1 factor (61.2%). [1+]. 















  Methodological 
quality 



















Result (quality rating) 
[89] AES-S         1 Adequate. 2 Very 
good.  
1 met hypothesis (1+). 2 
did not meet hypothesis 
(2-). 




3 factors (59.54%; 
variance explained per 
factor not reported.) 
[1?] 
2 Very good. α=.90 to .92. 
(2+). 
    2 Doubtful. 4 
Adequate. 4 Very 
Good. 
5 met hypothesis (5+). 3 
did not meet hypothesis 
(3-). 
[80] AI-C     1 Doubtful. ICC=.97 (1+).   1 Inadequate. 1 met hypothesis (1+). 
[72] AI-C   1 Doubtful. α=.83. (1?).       
[34] AI-I   1 Doubtful. α=.84. (1?). 1 Doubtful. 1 
Inadequate. 
Kappa= .96 to 
.99 (2+). 
  1 Adequate. 3 Very 
Good. 
3 met hypothesis (3+). 1 
did not meet hypothesis 
(1-).  
[72] AI-I   1 Doubtful. α=.83. (1?).       
[34] AI-S         3 Very Good. 1 met hypothesis. (1+). 2 
did not (2-) 
[72] AI-S   1 Doubtful. α=.61. (1?).       
[67] AMI   * α=.86     2 Adequate. 2 did not meet 
hypothesis (2-). 
[58] AS-HC 1 Very Good. 1 factor CFI=1.00, 
RMSEA=0.00. [1+] 
1 Very Good α=.94. (1+).     1 Very Good. 1 did not meet 
hypothesis (1-). 
[90] AS-I          1 Inadequate. 1 
Doubtful. 1 Very 
Good. 
1 met hypothesis (1+). 1 
did not meet hypothesis 
(1-). 1 insufficient 
information available 
(1?). 
[59] AS-S  1 Doubtful. 13-item: 3 factors 
(55.61%). Variance 
explained per factor 
not reported. [1?] 
2 Doubtful. 14 item 
version: 
α=.82.  















  Methodological 
quality 























[36] AS-S   1 Doubtful. α=.76. (1?). 2 Doubtful. r=.81 to .90. 
(2+). 
  1 Doubtful. 1 met hypothesis (1+). 
[58] AS-S 1 Very Good. 1 factor. CFI=1.00, 
RMSEA=0.00. [1+]. 
 
        
[60] AS-S 2 Adequate. 14-item: 2 factors 
(57.7%): Cognitive-
Behavioural (24.2%); 
Apathy and insight 
(15.05%). [1-]. 
13-item: 2 factors 
(41.7%) Variance 
explained per factor 
not reported. [1?] 




    1 Adequate. 2 Very 
Good.  
3 met hypothesis (3+). 
[77] AS-S   1 Inadequate. Guttman’s λ 
= .89. (1?). 
1 Inadequate. ICC=.78 (1+). n/a SEM = 2.34. 
(1?). 
1 Doubtful. 2 Very 
Good. 
1 met hypothesis (1+). 1 
did not meet hypothesis 
(1-). 1 insufficient 
information (1?). 
[61] AS-S 1 Very Good. 1 
Adequate. 
AS-S: 3 factors (nr). 
[1+/-]. 
11 item: 2 factors: 






      
[91] AS-S   1 Doubtful. α=.78. (1?).     1 Inadequate. 2 
Doubtful. 1 Very 
good. 
3 met hypothesis (3+). 1 
did not meet hypothesis 
(1-). 
[42] BMDS     1 Inadequate. r=.90. (1+)     
[43] BSSD   1 Doubtful. α=.82 to .83 
(1?) 
1 Inadequate. 3 
Doubtful. 
ICC=.65 to 
.85. (2+, 2-). 
  2 Inadequate. 1 
Doubtful. 1 Very 
Good. 
1 met hypothesis (1+). 1 















  Methodological 
quality 



















Result (quality rating) 
(1-). 2 insufficient 
information (2?). 
[37] DAIR 1 Adequate. 1 factor (38%) [1+] 1 Very Good. α=.89. (1+). 1 Inadequate. r=.85 (1+) 1 Doubtful. 100% 
agreement 
(1+). 
2 Inadequate. 2 
Very Good. 
3 met hypothesis (3+). 1 
did not meet hypothesis 
(1+). 
[75] DAS-I   * α=.92 
 
    2 Adequate. 1 met hypothesis (1+). 1 
did not meet hypothesis 
(1-). 
[74] DAS-I   * α=.93     2 Adequate. 2 met hypothesis (2+). 
[75] DAS-S   * α=.84     2 Adequate. 1 met hypothesis (1+). 1 
did not meet hypothesis 
(1-). 
[74] DAS-S   * α=.85     2 Adequate. 2 met hypothesis (2+). 





* α=.87     4 Adequate. 2 Very 
Good. 
4 met hypothesis (4+). 2 
did not meet hypothesis 
(2-). 
[63] bDAS * Item Hi=.40 to .76. No 
other fit measures 
reported. 
        
[76] bDAS   * α=.81. 1 Inadequate. ICC=.84 (1+).     
[81] DEX     1 Doubtful. ICC=.93 (1+).   1 Inadequate. 1 
Adequate. 2 Very 
Good. 
2 met hypothesis (2+). 2 
did not meet hypothesis 
(2+) 
[64] FrSBe-6a   1 Doubtful. α=.88. (1?).       
[68] FrSBe-
11a 
  1 Doubtful. α=.83. (1?).       
[68] FrSBe-
14a 
  1 Doubtful. α=.88. (1?).     6 Doubtful. 5 met hypothesis (5+). 1 
















  Methodological 
quality 



















Result (quality rating) 
[64] FrSBe-
14a 
1 Inadequate. 1 Factor specified: 12 
out of 14 items had 
loadings >.40. (nr). [1?]. 
1 Doubtful. α=.80. (1?).       
[92] GDS-3a         2 Adequate. 2 did not meet 
hypothesis. (2+). 
[69] GDS-6a   1 Doubtful. α=.51 (1?).     1 Doubtful. 2 
Adequate. 








    1 Doubtful. ICC=.83 (1+.) n/a SEM=1.38. (1?)   
[49] IMD         1 Inadequate. 3 
Doubtful. 
3 met hypothesis (3+). 1 
insufficient information 
(1?). 
[93] KBCI         1 Inadequate. 1 
Doubtful. 5 
Adequate. 
6 met hypothesis (6+). 1 
did not meet hypothesis 
(1-). 
[83] LARS-C     2 Doubtful. ICC=.94 to .99 
(2+). 
  2 Inadequate. 2 
Doubtful. 5 Very 
Good. 
7 met hypothesis (7+). 1 
did not meet hypothesis 
(1-). 1 insufficient 
information (1?). 
[65] LARS-C * 4 factors (67.5%): 
intellectual curiosity 
(nr); emotion (nr); 
action-initiation (nr); 
self awareness (nr). 
* α=.81. (*). 2 Doubtful. ICC= .97.  
(1+). Kappa = 
.93 (1+). 
  1 Inadequate. 2 
Adequate. 
2 met hypothesis (2+). 1 
did not meet hypothesis 
(1-). 
[70] LARS-I   * α=.87. (*). 2 Doubtful. ICC =.99. (1+). 
. (1+)ICC =.99. 
(1+). 
  2 Adequate. 2 met hypothesis (2+). 
[84] NPI     1 Doubtful. 1 
Inadequate. 
ICC = .67 (1-).  
rs= .53 (1-). 















  Methodological 
quality 



















Result (quality rating) 
[94] NPI         2 Doubtful. 2 insufficient information 
(2?). 
[51] NPI         1 Doubtful. 1 insufficient information 
(1?). 
[85] NPI     1 Inadequate r=.96 (1+).   1 Doubtful. 1 insufficient information 
(1?). 




  1 Inadequate. 1 
Doubtful. 1 Very 
Good. 
1 met hypothesis (1+). 1 
did not meet hypothesis 
(1-). 1 insufficient 
information (1?). 
[95] NPI         1 Inadequate. 1 did not meet 
hypothesis (1-). 
[79] NPI   1 Doubtful. α=.83 (1?) 1 Doubtful. Kendell CC= 
1.00 (1+). 
  1 Inadequate. 1 did not meet 
hypothesis (1-). 
[96] NPI         1 Very Good. 1 did not meet 
hypothesis (1-). 
[86] NPI     1 Doubtful. ICC=.99 (1+).     
[66] NPI-A 1 Adequate. 1 factor (66%). [1+]. 1 Very Good. α=.91 (1+)       
[87] NPI-C     1 Doubtful. Item ICC= .74 
to .89 (1+). 
  1 Adequate. 1 did not meet 
hypothesis (1-). 
[88] NPI-C     1 Doubtful. ICC=.87 (1+).   1 Adequate. 1 met hypothesis (1+). 
[97] mds-
UPDRS  
        1 Very Good. 1 met hypothesis (1+). 
[98] UPDRS         1 Adequate. 1 met hypothesis (1+). 
[99] UPDRS         1 Inadequate. 2 
Very Good.  
3 did not meet 
hypothesis (3-). 
[100] UPDRS         1 Very Good. 1 met hypothesis (1+). 
Blank cells indicate this measurement property was not investigated. 93 
*Was assessed by the study, but methodological quality rating nor quality rating of result conducted, as the measure is based on a formative model. 94 
^ Value calculated by review team based on information provided in the article. 95 
Quality of measurement property: Number of studies in parenthesis followed by rating: +, Sufficient; +/-, Inconsistent; -, Insufficient; ?, Indeterminate.  96 
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Abbreviations: +, Sufficient; -, Insufficient; ?, Indeterminate; AD-RD, Alzheimer's Disease and Related Dementias Mood Scale; AES-12PD, Apathy Evaluation Scale for Parkinson Disease; AES-C, 97 
Apathy Evaluation Scale Clinician; AES-I, Apathy Evaluation Scale Informant; AES-I-16, Apathy Evaluation Scale Informant 16 item version; AES-S, Apathy Evaluation Scale Self; AI-C, Apathy 98 
Inventory Clinician; AI-I, Apathy Inventory Informant; AI-S, Apathy Inventory Self; AMI, Apathy Motivation Index; AS-HC, Apathy Scale Home Care; AS-I, Apathy Scale Informant; AS-S, Apathy 99 
Scale Self; b-DAS, brief-Dimensional Apathy Scale; BMDS, Behavioural and Mood Disturbance Scale; BSSD, Behavioral Syndromes Scale for Dementia; DAIR, Dementia Apathy Interview 100 
Rating; DAS-I, Dimensional Apathy Scale Informant; DAS-S, Dimensional Apathy Scale Self; DEX, Dysexecutive Questionnaire; FrSBe-6a, Frontal Systems Behavior Scale 6-item apathy 101 
subscale; FrSBe-11a, Frontal Systems Behavior Scale 11-item apathy subscale; FrSBe-14a, Frontal Systems Behavior Scale 14-item apathy subscale; GDS-3a, Geriatric Depression Scale 3 item 102 
apathy subscale; GDS-6a, Geriatric Depression Scale 6 item apathy subscale GIP, Behavioral Rating Scale for Psychogeriatric Inpatients; IMD, Index of Mental Decline; KBCI, Key Behaviors 103 
Change Inventory; LARS-C, Lille Apathy Rating Scale Clinician; LARS-I, Lille Apathy Rating Scale Informant; mds-UPDRS, Movement Disorder Society-Sponsored Revision of the Unified 104 
Parkinson’s Disease Rating Scale; NPI, Neuropsychiatric Inventory; NPI-A, Neuropsychiatric Inventory Alternative; NPI-C, Neuropsychiatric Inventory Clinician; nr, not reported; UPDRS, 105 
Unified Parkinson’s Disease Rating Scale  106 
Where there is no rating available for the researcher, this means it was not possible to obtain sufficient information regarding the measure to assess its content validity. Ratings of content 107 
validity are for both people with dementia or MCI and older adults unless otherwise specified. 108 
 109 
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